Kratos, continues to gain dominance in the field of highly specialized national security technology and providing a complete mission critical products/services envelope, reporting today successful nomination for two separate, influential awards in IT and middle marketing for the recent Herley Industries, Inc. acquisition at the 10th Annual M&A Advisor Awards Gala, held at the New York Athletic Club, NY this Dec. 13.
Senior Markets Desk Reporter for Bloomberg, Julie Hyman, hosted the event, where both award nominations were conferred upon KTOS simultaneously for the Herley deal, seen by many as a real masterstroke:
2012 Information Technology Award – $100M and over
2011 Middle Market Deal of the Year – $250-400M
Herley’s infrastructural competencies extend KTOS’s own striking distance beautifully, bringing the industry-leading design, development and manufacturing expertise in defense/aerospace microwave technology for which Herley is known, to the table alongside the Company’s own deep proficiencies in manufacturing and engineering related to National Security platforms/programs.
Herley already has solid footing in a variety of key US national security related programs/platforms and the acquisition of this Woburn, MA-based shop adds robust vectors to KTOS’s seven-facility manufacturing (~1k employee) Weapons Systems Solutions Division, into which the acquisition was integrated.
Great news for KTOS, following fast on the heels of the announcement Dec. 12, that the Company was recognized at this year’s M&A Advisor Deals of the Decade Celebration at the Museum of American Finance, with the 2009 Turnaround of the Year Award.
President and CEO of KTOS, Eric DeMarco, beamed with enthusiasm at being recognized once more by the prestigious M&A Advisor Awards, recognition which boldly underlines the outstanding success of KTOS’s M&A Team, as well as the integration team which spearheads such momentum building acquisitions. DeMarco pointed to this clear recognition of the Company’s “continued execution” of the strategic business plan to create the “C5ISR focused engineering, technology and specialty products based National Security Solutions provider in the industry.”
Senior VP of the Strategy and Corporate Development Division at KTOS, James Cotter, echoed this enthusiasm and detailed the exceptional microwave/specialty platforms experience Herley ads to the mix, pointing to growing dependence on such capabilities by a number of critical US infrastructure like the EA-18G Electronic Attack Aircraft and a host of other Ballistic Missile Defense Programs.
For more information on the nominations/awards or for more information on Kratos Defense & Security Solutions, Inc. and the Company’s numerous engineering and technical capabilities in a spectrum of high security cleared environments, or on the Herley acquisition itself, please visit the Company’s website at: www.KratosDefense.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Friday, December 30, 2011
JA Solar Holdings Co., Ltd., (JASO) Announces Exclusive Deal To Supply 19 MW Solar Modules For Utility Scale Solar Power Project In Germany
JA Solar Holdings Co. Ltd, one of the world’s largest manufacturers of high-performance solar cells and solar power products, today announced an exclusive deal with Solarhybrid AG (SHL) a Germany-based project developer and general contractor for turn-key utility-scale solar power projects, to supply 19 MW of high-efficiency solar modules to the Allstedt I solar power plant in Halle, Germany. The Allstedt I power plant should generate 19,030,000 kWh of electricity annually by the end of this year when it is connected to the grid. The project will also reduce CO2 emissions by 266,381 tons over its expected 20 years of service.
“We are delighted to work with Solarhybrid as the exclusive module supplier to the Allstedt I solar power project,” said Dr. Peng Fang, CEO, JA Solar in a recent press release. “As this project demonstrates, demand and support for solar energy are strong in Germany. We look forward to working closely with Solarhybrid to ensure the success of this project and to take advantage of future growth opportunities in Germany and beyond.”
Since 2005, JA Solar has manufactured high-performing solar power products to sell worldwide and in 2010 established itself as the world leader in solar cell production shipping 1.46 GW over the course of the year. Revenues for 2010 totaled $1.78 billion up 211% from 2009. JA Solar was first in terms of solar cells produced and shipped globally in Q3 2010 according to reports published in SolarBuzz and IMS Research.
“Following a stringent supplier selection process, we are very pleased to choose JA Solar, a proven provider of industry leading solar products, as our partner for this project. JA Solar’s cost-effective, high-efficiency solutions will enable us to maximize the return on investment in this project. With JA Solar’s support, we look forward to opening the Allstedt I power plant by end of this year,” said Tom Schroder, CEO, Solarhybrid in the press release.
JA Solar ships its solar power products to solar manufacturers who assemble and integrate the solar cells into modules and systems designed to convert sunlight into electricity for utility-scale power generation. The Solarhybrid deal is expected to reach approximately 40 MW of total modules shipped by 2011 which includes the 19MW to be used for the Allstedt I project.
For more information, please visit www.jasolar.com and www.solarhybrid.ag
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“We are delighted to work with Solarhybrid as the exclusive module supplier to the Allstedt I solar power project,” said Dr. Peng Fang, CEO, JA Solar in a recent press release. “As this project demonstrates, demand and support for solar energy are strong in Germany. We look forward to working closely with Solarhybrid to ensure the success of this project and to take advantage of future growth opportunities in Germany and beyond.”
Since 2005, JA Solar has manufactured high-performing solar power products to sell worldwide and in 2010 established itself as the world leader in solar cell production shipping 1.46 GW over the course of the year. Revenues for 2010 totaled $1.78 billion up 211% from 2009. JA Solar was first in terms of solar cells produced and shipped globally in Q3 2010 according to reports published in SolarBuzz and IMS Research.
“Following a stringent supplier selection process, we are very pleased to choose JA Solar, a proven provider of industry leading solar products, as our partner for this project. JA Solar’s cost-effective, high-efficiency solutions will enable us to maximize the return on investment in this project. With JA Solar’s support, we look forward to opening the Allstedt I power plant by end of this year,” said Tom Schroder, CEO, Solarhybrid in the press release.
JA Solar ships its solar power products to solar manufacturers who assemble and integrate the solar cells into modules and systems designed to convert sunlight into electricity for utility-scale power generation. The Solarhybrid deal is expected to reach approximately 40 MW of total modules shipped by 2011 which includes the 19MW to be used for the Allstedt I project.
For more information, please visit www.jasolar.com and www.solarhybrid.ag
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
ARCA biopharma (ABIO) receives Patent for Methods of Treatment with Bucindolol
ARCA biopharma Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, has been awarded a patent from the U.S. Patent and Trademark Office (USPTO) for the company’s methods of treating patients with bucindolol based on genetic targeting and focused on a specific genotype (homozygous wildtype for Deletion 322-325 in the alpha-2C adrenergic receptor).
The patent entitled “Methods for Treatment with Bucindolol Based on Genetic Targeting” provides patent protection in the United States for the company’s approach to treating patients with bucindolol.
Dr. Michael Bristow, CEO of ARCA biopharma, emphasized the challenges surrounding cardiovascular diseases and how new therapies can address these challenges.
“We are obviously pleased with the USPTO’s issuance of this patent, which we believe extends our pharmacogenetic intellectual property protection around bucindolol,” Dr. Bristow stated in the press release. “Chronic cardiovascular diseases continue to be a major health care problem, and among the challenges to improving care is the uncertainty of patient responses to drug treatment. We believe new therapies that include a simple test to identify a substantial subpopulation of patients more likely to benefit have the potential to alleviate some of the problems encountered with the current standard of pharmacotherapy, where all members of a disease cohort, including those who will not respond, are treated.”
Dr. Bristow said bucindolol is exclusive in its ability to lower the hormone responsible for increasing blood pressure and rate and depth of breathing, as well as raising blood sugar levels and decreasing activity of the intestines.
“A unique pharmacologic property of bucindolol is norepinephrine lowering, and bucindolol’s heart failure clinical responses demonstrated in a large phase 3 clinical trial (BEST) were modulated by this important effect. … Accordingly, we believe prospective knowledge … allows for prediction of the degree of norepinephrine lowering by bucindolol in an individual patient,” Dr. Bristow concluded.
For more information visit www.arcabiopharma.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The patent entitled “Methods for Treatment with Bucindolol Based on Genetic Targeting” provides patent protection in the United States for the company’s approach to treating patients with bucindolol.
Dr. Michael Bristow, CEO of ARCA biopharma, emphasized the challenges surrounding cardiovascular diseases and how new therapies can address these challenges.
“We are obviously pleased with the USPTO’s issuance of this patent, which we believe extends our pharmacogenetic intellectual property protection around bucindolol,” Dr. Bristow stated in the press release. “Chronic cardiovascular diseases continue to be a major health care problem, and among the challenges to improving care is the uncertainty of patient responses to drug treatment. We believe new therapies that include a simple test to identify a substantial subpopulation of patients more likely to benefit have the potential to alleviate some of the problems encountered with the current standard of pharmacotherapy, where all members of a disease cohort, including those who will not respond, are treated.”
Dr. Bristow said bucindolol is exclusive in its ability to lower the hormone responsible for increasing blood pressure and rate and depth of breathing, as well as raising blood sugar levels and decreasing activity of the intestines.
“A unique pharmacologic property of bucindolol is norepinephrine lowering, and bucindolol’s heart failure clinical responses demonstrated in a large phase 3 clinical trial (BEST) were modulated by this important effect. … Accordingly, we believe prospective knowledge … allows for prediction of the degree of norepinephrine lowering by bucindolol in an individual patient,” Dr. Bristow concluded.
For more information visit www.arcabiopharma.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Onyx Service & Solutions Inc. (ONYX) Develops Engineering Plan for Roatan Project
Today, Onyx Service & Solutions announced that it has developed a plan to successfully distribute power on its new 22-megawatt project in Roatan, Honduras. With problems arising from an older distribution system, the plan will provide a fix to the numerous issues Roatan has faced with power outages.
Onyx’s detailed engineering research has developed an alternative that breaks the solar placement up into many smaller “farms” that can be strategically placed, down to a single user “at-meter” solution. ONYX plans to use a cutting-edge repository system for the larger production farms and may decide to utilize its new “Plug-N-Play” panel for smaller output areas. Repository systems store energy for use after the sun has gone down or if there is not ample sunlight for extended periods of time. ONYX’s new “Plug-N-Play” panel already has a battery unit and inverter integrated into the panel straight from the factory.
“There has been abundant discussions about addressing the distribution system issue”, stated Malcolm Burleson, President of ONYX. “The fact that solar can be downsized all the way to a single panel, plus our access to superior energy storage options, gives us great latitude in distribution. It certainly eliminates many standard distribution factors, especially any need for large and costly transmission stations.”
Onyx decided to forgo the normal strategies employed by solar companies, such as competing against coal-fired electricity producers or depending on government subsidies to make a profit. Instead, Onyx management identified sectors that rely on costly diesel generated electricity, like Roatan, to focus on as its target market. These sectors present higher profit margins and more profit making opportunities.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Onyx’s detailed engineering research has developed an alternative that breaks the solar placement up into many smaller “farms” that can be strategically placed, down to a single user “at-meter” solution. ONYX plans to use a cutting-edge repository system for the larger production farms and may decide to utilize its new “Plug-N-Play” panel for smaller output areas. Repository systems store energy for use after the sun has gone down or if there is not ample sunlight for extended periods of time. ONYX’s new “Plug-N-Play” panel already has a battery unit and inverter integrated into the panel straight from the factory.
“There has been abundant discussions about addressing the distribution system issue”, stated Malcolm Burleson, President of ONYX. “The fact that solar can be downsized all the way to a single panel, plus our access to superior energy storage options, gives us great latitude in distribution. It certainly eliminates many standard distribution factors, especially any need for large and costly transmission stations.”
Onyx decided to forgo the normal strategies employed by solar companies, such as competing against coal-fired electricity producers or depending on government subsidies to make a profit. Instead, Onyx management identified sectors that rely on costly diesel generated electricity, like Roatan, to focus on as its target market. These sectors present higher profit margins and more profit making opportunities.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
IVAX Diagnostics (IVD) Amends Major Stock Purchase Agreement With ERBA Diagnostics
Miami-based IVAX Diagnostics, an in-vitro diagnostics company, has entered into an amendment to an April 8, 2011, agreement with ERBA Diagnostics Mannheim GmbH, in which IVAX agreed to sell to ERBA 20 million shares of IVAX common stock at a price of $0.75 per share, plus warrants to purchase an additional 20 million shares, with the purchases spread over three separate closings.
The amendment changes the terms relating to the timing of the second closing and the final closing. Instead of the second closing occurring 6 months or less after the initial closing, it will now occur 60 days after the date on which a majority of the independent directors on IVAX Diagnostics’ Board of Directors determines by vote or written consent that the second closing shall occur. Instead of the final closing occurring one year or less after the initial closing, it will now occur after or simultaneously with the second closing, 60 days after the date on which a majority of the independent directors on IVAX Diagnostics’ Board of Directors determines by vote or written consent that the final closing shall occur.
The amendment basically gives IVAX more flexibility in controlling the timing of the associated transactions. IVAX President, CEO, and COO, Kevin Clark, said of the amendment: “We are pleased that, through this Amendment to the Stock Purchase Agreement, the independent directors on our Board of Directors will be able to trigger the timing of the consummation of the Second Closing and the Final Closing based upon IVAX Diagnostics’ cash requirements, including for funding the continued growth and development of our business and working capital requirements, and for possible acquisitions and strategic opportunities. This Amendment to the Stock Purchase Agreement will also have the effect of moving the timing of the dilutive impact that would be caused by the issuance to ERBA Diagnostics Mannheim of additional shares of IVAX Diagnostics’ common stock at the Second Closing and the Final Closing. We are also excited to report that, principally due to the expected relative improvement in our operations and the expected relative reduction in the rate of our use of cash during the fourth quarter of 2011, we believe that the immediacy of our need for additional cash has diminished.”
ERBA already owns, directly or indirectly, 26,701,380 shares of IVAX Diagnostics’ common stock, or approximately 77.6% of the issued and outstanding shares of IVAX Diagnostics’ common stock.
IVAX Diagnostics develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, through its three subsidiaries: Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe), and ImmunoVision, Inc. (U.S.).
For additional information on IVAX Diagnostics, visit www.IVAXDiagnostics.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The amendment changes the terms relating to the timing of the second closing and the final closing. Instead of the second closing occurring 6 months or less after the initial closing, it will now occur 60 days after the date on which a majority of the independent directors on IVAX Diagnostics’ Board of Directors determines by vote or written consent that the second closing shall occur. Instead of the final closing occurring one year or less after the initial closing, it will now occur after or simultaneously with the second closing, 60 days after the date on which a majority of the independent directors on IVAX Diagnostics’ Board of Directors determines by vote or written consent that the final closing shall occur.
The amendment basically gives IVAX more flexibility in controlling the timing of the associated transactions. IVAX President, CEO, and COO, Kevin Clark, said of the amendment: “We are pleased that, through this Amendment to the Stock Purchase Agreement, the independent directors on our Board of Directors will be able to trigger the timing of the consummation of the Second Closing and the Final Closing based upon IVAX Diagnostics’ cash requirements, including for funding the continued growth and development of our business and working capital requirements, and for possible acquisitions and strategic opportunities. This Amendment to the Stock Purchase Agreement will also have the effect of moving the timing of the dilutive impact that would be caused by the issuance to ERBA Diagnostics Mannheim of additional shares of IVAX Diagnostics’ common stock at the Second Closing and the Final Closing. We are also excited to report that, principally due to the expected relative improvement in our operations and the expected relative reduction in the rate of our use of cash during the fourth quarter of 2011, we believe that the immediacy of our need for additional cash has diminished.”
ERBA already owns, directly or indirectly, 26,701,380 shares of IVAX Diagnostics’ common stock, or approximately 77.6% of the issued and outstanding shares of IVAX Diagnostics’ common stock.
IVAX Diagnostics develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, through its three subsidiaries: Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe), and ImmunoVision, Inc. (U.S.).
For additional information on IVAX Diagnostics, visit www.IVAXDiagnostics.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, December 29, 2011
Is Silver a Buy Again?
Silver has never been an investment for the faint of heart and 2011 has only added to its reputation as a capricious beast. From just over $30 when the year began, it dropped to $27 within a month, then rocketed to over $48 by early spring, only to free-fall to the mid $30s within a couple of weeks. By late summer, silver had worked its way back into the low $40s, but then collapsed again to just over $30 by October. After a push to the mid $30s, silver has now fallen back to the upper $20s, essentially where it was in late January, making a case for a buy at what some consider support levels, notwithstanding the fact that silver bounced between $10 and $20 for nearly 5 years prior to mid-2010.
But the real story of silver is not its short term volatility. It’s the fact that it is disappearing from the supply chain faster than almost any commodity in history. Unlike gold, which, once torn from the ground, tends to stay in place, not even losing its luster, silver is now being eaten up. The name of the devouring monster: electronics. The explosion in cell phones and other electronic devices and related industrial processes in the last couple of decades has created a demand-future for silver that is only now being seriously evaluated.
The demand for silver in electronics has roughly doubled in the past 10 years. For the first time in history, electronics consumes more silver than jewelry and silverware, the previous primary uses. And that’s key, since jewelry, as an example, is often stored and recycled, while silver used in electronics is simply lost to landfills. Today we are consuming more silver than mines produce, and the effect is accelerating. Add to this the fact that China and India are growing consumers of silver for electronic devices, with China becoming a major silver importer versus its earlier role as a silver exporter.
The net result is that global silver reserves are drying up faster than a Texas lake. Unlike with gold, the world today has only a small fraction of the silver now that it had a century ago. It’s a changing dynamic that many investors fail to appreciate, looking upon silver in its historic role as a monetary hedge. The price of silver, today being kicked around based upon the rise and fall of economies and currencies, will soon be viewed far differently.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
But the real story of silver is not its short term volatility. It’s the fact that it is disappearing from the supply chain faster than almost any commodity in history. Unlike gold, which, once torn from the ground, tends to stay in place, not even losing its luster, silver is now being eaten up. The name of the devouring monster: electronics. The explosion in cell phones and other electronic devices and related industrial processes in the last couple of decades has created a demand-future for silver that is only now being seriously evaluated.
The demand for silver in electronics has roughly doubled in the past 10 years. For the first time in history, electronics consumes more silver than jewelry and silverware, the previous primary uses. And that’s key, since jewelry, as an example, is often stored and recycled, while silver used in electronics is simply lost to landfills. Today we are consuming more silver than mines produce, and the effect is accelerating. Add to this the fact that China and India are growing consumers of silver for electronic devices, with China becoming a major silver importer versus its earlier role as a silver exporter.
The net result is that global silver reserves are drying up faster than a Texas lake. Unlike with gold, the world today has only a small fraction of the silver now that it had a century ago. It’s a changing dynamic that many investors fail to appreciate, looking upon silver in its historic role as a monetary hedge. The price of silver, today being kicked around based upon the rise and fall of economies and currencies, will soon be viewed far differently.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
JA Solar (JASO) Announces Supply Agreement with Solarhybrid for Project in Germany
China-based JA Solar Holdings Company Ltd. is one of the world’s largest manufacturers of high-performance solar cells and solar power products. The company sells its products worldwide, converting sunlight into electricity for residential, commercial and utility customers.
The company today announced that it has entered into an agreement with Solarhybrid AG, a German project developer and general contractor for turnkey utility-scale solar power projects. JA Solar will supply 19 megawatts of solar modules to Solarhybrid’s Allstedt I solar power plant in Halle, Germany and be the exclusive solar module provider to the project.
The Allstedt I solar power plant is expected to generate just over 19 million kilowatts of electricity annually and reduce carbon dioxide emissions by more than 266,000 tons over a service period of 20 years. The power plant is scheduled to be connected to the grid and begin operations very soon.
JA Solar expects total module shipments to Solarhybrid to reach 40 megawatts this year, including the 19 megawatts for the Allstedt I project. For additional information on JA Solar, please visit the company’s website at www.jasolar.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The company today announced that it has entered into an agreement with Solarhybrid AG, a German project developer and general contractor for turnkey utility-scale solar power projects. JA Solar will supply 19 megawatts of solar modules to Solarhybrid’s Allstedt I solar power plant in Halle, Germany and be the exclusive solar module provider to the project.
The Allstedt I solar power plant is expected to generate just over 19 million kilowatts of electricity annually and reduce carbon dioxide emissions by more than 266,000 tons over a service period of 20 years. The power plant is scheduled to be connected to the grid and begin operations very soon.
JA Solar expects total module shipments to Solarhybrid to reach 40 megawatts this year, including the 19 megawatts for the Allstedt I project. For additional information on JA Solar, please visit the company’s website at www.jasolar.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Peregrine Pharmaceuticals (PPHM) Announces Preliminary Results for Phase II Hepatitis Study
Peregrine Pharmaceuticals Inc., a biopharmaceutical company focused on developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today issued an update on its randomized phase II bavituximab study in patients infected with genotype-1 chronic hepatitis C virus (HCV).
The goals of the study were to compare the safety profile of bavituximab plus ribavirin with a interferon and ribavirin combination.
Preliminary data indicates that the combination of bavituximab and ribavirin appeared safe and well-tolerated in patients who reported fewer side effects than in the interferon-containing arm. The study also indicated that both dose levels of bavituximab with ribavirin demonstrated antiviral activity, however the antiviral effects in patients receiving the 0.3 mg/kg dosing level were more pronounced.
“We are pleased with the initial results we have seen from this clinical study evaluating the combination of bavituximab with an established antiviral drug in HCV patients. We see good evidence that the combination of bavituximab with ribavirin has a better safety profile than an interferon containing regimen which was one of the primary objectives of the study,” Joseph S. Shan, vice president of clinical and regulatory affairs at Peregrine stated in the press release.
Shan also noted that while both dose levels of bavituximab were active, the lower dose level appears more active in HCV patients than the high dose level, and that these preliminary results are important in validating that the combination of bavituximab with its immunological mechanism of action with an active antiviral agent that has a good safety profile and promising antiviral activity.
“These results suggest that future studies evaluating longer bavituximab treatment durations at or around the lower dose level in combination with ribavirin and potentially direct acting antivirals in certain patient populations may hold promise as interferon-free HCV therapeutic regimens,” Shan stated.
“The early data from this trial are promising and suggest that continued development of bavituximab in HCV patients is warranted to explore the full immune-modulating potential of the compound in combination with antiviral agents,” added Shan.
Steven W. King, president and CEO of Peregrine, said the company will use the data to seek development partners interested in advancing the PS-targeting antiviral program. Peregrine will continue to focus its resources on its bavituximab oncology clinical program.
The company said it plans to present full results from the study at a medical conference in 2012.
For more information visit www.peregrineinc.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The goals of the study were to compare the safety profile of bavituximab plus ribavirin with a interferon and ribavirin combination.
Preliminary data indicates that the combination of bavituximab and ribavirin appeared safe and well-tolerated in patients who reported fewer side effects than in the interferon-containing arm. The study also indicated that both dose levels of bavituximab with ribavirin demonstrated antiviral activity, however the antiviral effects in patients receiving the 0.3 mg/kg dosing level were more pronounced.
“We are pleased with the initial results we have seen from this clinical study evaluating the combination of bavituximab with an established antiviral drug in HCV patients. We see good evidence that the combination of bavituximab with ribavirin has a better safety profile than an interferon containing regimen which was one of the primary objectives of the study,” Joseph S. Shan, vice president of clinical and regulatory affairs at Peregrine stated in the press release.
Shan also noted that while both dose levels of bavituximab were active, the lower dose level appears more active in HCV patients than the high dose level, and that these preliminary results are important in validating that the combination of bavituximab with its immunological mechanism of action with an active antiviral agent that has a good safety profile and promising antiviral activity.
“These results suggest that future studies evaluating longer bavituximab treatment durations at or around the lower dose level in combination with ribavirin and potentially direct acting antivirals in certain patient populations may hold promise as interferon-free HCV therapeutic regimens,” Shan stated.
“The early data from this trial are promising and suggest that continued development of bavituximab in HCV patients is warranted to explore the full immune-modulating potential of the compound in combination with antiviral agents,” added Shan.
Steven W. King, president and CEO of Peregrine, said the company will use the data to seek development partners interested in advancing the PS-targeting antiviral program. Peregrine will continue to focus its resources on its bavituximab oncology clinical program.
The company said it plans to present full results from the study at a medical conference in 2012.
For more information visit www.peregrineinc.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, December 28, 2011
Quantum Fuel Systems Technologies Worldwide (QTWW) Enters Strategic Relationship with Major Wind Turbine Manufacture to Finance and Develop Wind Farms Globally
Quantum Fuel Systems Technologies Worldwide, Inc., a fully integrated alternative energy company, in conjunction with their wholly-owned subsidiary Schneider Power, Inc., one of Canada’s premier renewable energy companies, recently announced a new strategic agreement between Schneider’s wholly-owned subsidiary, Trout Creek Wind Power, and a major global wind turbine manufacturer for the financing and development of wind farms in North America.
Terms of the deal include that the manufacture will provide a maximum of CDN $24 Million dollars for financing the construction of the generation facility. The Company will utilize the manufacturer’s wind turbines at the 10 MW Trout Creek Wind Farm in Ontario, Canada. Both parties anticipate closure on the deal by December 31, 2012 and agree to meet the 50% local content requirement from the Ontario Government.
“We are excited about this relationship as it provides an opportunity for us to finance the Trout Creek and potentially other wind farms while retaining 100% ownership in each project. We are hopeful that the Trout Creek agreement will be the first among a broader strategic relationship aimed at financing and developing Schneider Power’s global portfolio of 1,000 MW of wind farms,” said Alan Niedzwiecki, Quantum’s CEO in a press release.
Schneider Power has successfully completed the required wind studies to finalize the wind farm and the final environmental permitting is underway. The construction of the renewable energy generation facility is expected to be completed on schedule.
Trout Creek Wind Farm will produce electricity for the Ontario Power Authority as authorized in a 20-year purchase agreement with the Ontario Government’s Feed-In-Tariff program at a rate of $135/MWH starting in the fall of 2013. The local utility Hydro One Networks, Inc. will help link the Wind Farm to an existing high voltage transmission line near the property.
In Canada, Schneider Power has a significant development portfolio of potential renewable power facilities in excess of 1,000 MW. Across North America, the company evaluates, designs, builds, owns and operates some of the most advanced renewable energy generation projects.
For more information, please visit www.qtwww.com or www.schneiderpower.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Terms of the deal include that the manufacture will provide a maximum of CDN $24 Million dollars for financing the construction of the generation facility. The Company will utilize the manufacturer’s wind turbines at the 10 MW Trout Creek Wind Farm in Ontario, Canada. Both parties anticipate closure on the deal by December 31, 2012 and agree to meet the 50% local content requirement from the Ontario Government.
“We are excited about this relationship as it provides an opportunity for us to finance the Trout Creek and potentially other wind farms while retaining 100% ownership in each project. We are hopeful that the Trout Creek agreement will be the first among a broader strategic relationship aimed at financing and developing Schneider Power’s global portfolio of 1,000 MW of wind farms,” said Alan Niedzwiecki, Quantum’s CEO in a press release.
Schneider Power has successfully completed the required wind studies to finalize the wind farm and the final environmental permitting is underway. The construction of the renewable energy generation facility is expected to be completed on schedule.
Trout Creek Wind Farm will produce electricity for the Ontario Power Authority as authorized in a 20-year purchase agreement with the Ontario Government’s Feed-In-Tariff program at a rate of $135/MWH starting in the fall of 2013. The local utility Hydro One Networks, Inc. will help link the Wind Farm to an existing high voltage transmission line near the property.
In Canada, Schneider Power has a significant development portfolio of potential renewable power facilities in excess of 1,000 MW. Across North America, the company evaluates, designs, builds, owns and operates some of the most advanced renewable energy generation projects.
For more information, please visit www.qtwww.com or www.schneiderpower.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
American Apparel (APP) Increases Presence in UK with New Store in London
American Apparel, a Los Angeles based vertically integrated manufacturer, distributor and retailer of branded fashion basic apparel, today announced that it has opened its 18th location in the UK at the Westfield London. The mall attracts nearly 30 million people each year. In the new Westfield London location, American Apparel will sell both women’s wear and unisex styles ranging from basics and staple garments to more high end fashion pieces and seasonal outerwear. This new store is only one piece in an expansion effort in the UK and Europe.
“Westfield London is one of the largest shopping centers in all of in the United Kingdom and we’re thrilled to be there. The people of London have always demonstrated a deep understanding of our brand. We’ve had great success together in Westfield Malls across the US and opening with them in London will be a significant addition to our foothold there. We’re pleased to have the opportunity to serve a new set of customers and expand our offerings for those already shopping at our stores,” said Marsha Brady, a creative director for American Apparel in a press statement.
American Apparel, with approximately 11,000 employees and 249 retail stores in 20 countries, went public in December 2007 following a merger with Endeavor Acquisition Corp. It is best known for its cutting-edge advertising and products that attract young adults and people of all ages. Being branded as a Downtown LA company has increased its name recognition and helped it to achieve a cult-like status. American Apparel does most of its knitting, dyeing, sewing, photography, marketing, distribution and design in its Los Angeles facilities without the use of many offshore contractors.
For more information on American Apparel, please visit www.americanapparel.net
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“Westfield London is one of the largest shopping centers in all of in the United Kingdom and we’re thrilled to be there. The people of London have always demonstrated a deep understanding of our brand. We’ve had great success together in Westfield Malls across the US and opening with them in London will be a significant addition to our foothold there. We’re pleased to have the opportunity to serve a new set of customers and expand our offerings for those already shopping at our stores,” said Marsha Brady, a creative director for American Apparel in a press statement.
American Apparel, with approximately 11,000 employees and 249 retail stores in 20 countries, went public in December 2007 following a merger with Endeavor Acquisition Corp. It is best known for its cutting-edge advertising and products that attract young adults and people of all ages. Being branded as a Downtown LA company has increased its name recognition and helped it to achieve a cult-like status. American Apparel does most of its knitting, dyeing, sewing, photography, marketing, distribution and design in its Los Angeles facilities without the use of many offshore contractors.
For more information on American Apparel, please visit www.americanapparel.net
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Magic Software Enterprises, Ltd. (MGIC) Acquires BluePhoneix’s AppBuilder Platform for $13.5 Million
Today, Magic Software Enterprises, Ltd. announced that it has acquired BluePhoneix’s AppBuilder activity for $13.5 million. AppBuilder is a comprehensive application development infrastructure that enables development teams to build, deploy, and maintain large-scale, custom-built business applications. Currently used by many Fortune 100 companies around the globe, AppBuilder is recognized in the industry as a powerful, model-driven tool.
According to the acquisition agreement, Magic Software paid out a net amount of $13.5 million. $4 million of the total purchase amount will be held in escrow accounts pending fulfillment of certain obligations of BluePhoenix under the sale agreement.
Regarding the acquisition, Guy Bernstein, CEO of Magic Software, remarked, “We are pleased to have completed this important acquisition, which broadens Magic Software’s product portfolio and strengthens our presence in numerous global markets, including Asia and Europe. We plan to develop and invest in all aspects of AppBuilder’s activity, including offering increased support for its customers.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
According to the acquisition agreement, Magic Software paid out a net amount of $13.5 million. $4 million of the total purchase amount will be held in escrow accounts pending fulfillment of certain obligations of BluePhoenix under the sale agreement.
Regarding the acquisition, Guy Bernstein, CEO of Magic Software, remarked, “We are pleased to have completed this important acquisition, which broadens Magic Software’s product portfolio and strengthens our presence in numerous global markets, including Asia and Europe. We plan to develop and invest in all aspects of AppBuilder’s activity, including offering increased support for its customers.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tracking the Illusive Gold Nugget Stock: AdCare Health Systems (ADK)
One of the classic gold nuggets for an investor is the micro-cap or small-cap company that is just starting to show up on radar screens, but with a strong history of growing revenue, and earnings that appear ready to break into positive territory. It’s a rare combination of qualities, offering investors one of the greatest potentials for substantial, short term profit. Once positive earnings are achieved, the effect on share price can be explosive.
There is a unique window of opportunity, and it doesn’t last long. As a company grows, drawing the attention of an increasing number of analysts, it becomes more a game of beating expectations. Eventually it’s no longer enough for the company to announce strong quarterly revenue and earnings numbers, the numbers have to beat analyst estimates. Also, when enough eyes are on the company, expectations can be built into the share price, allowing for a nasty tumble or major boost when earnings are announced. Everyone, including company executives, knows this, and companies do whatever they can to ensure that quarterly reports meet or beat expectations, out of concern that sudden well-publicized share price drops can send skittish investors away for good.
But, until that happens, while a company is still in that magic pre-blossom stage, an alert investor can line themselves up for a staggering short term gain. Even more desirable, of course, is when such a company is also positioned for continued long term growth, based upon efficient leveraging of an expanding market. Not every management team is smart enough to deal with the often hidden opportunities and challenges of market expansion. Companies can easily overextend themselves late in the cycle, generating an unsustainable financial burden just when the market turns south. If, however, management is able to stay ahead of the curve, taking advantage of low cost acquisitions before the boom, and understands how to grow and operate on increasing scales in advance of growing demand, the future holds few limits.
Take a look at AdCare Health Systems, an Ohio-based manager of senior living facilities. AdCare currently operates over 42 facilities in Ohio, Georgia, Alabama, Arkansas, and North Carolina, with new acquisitions continually being targeted. Facilities include independent living campuses, assisted living facilities, nursing homes, and dementia care facilities. The company also provides comprehensive home health care services. Facilities are either owned by AdCare, leased from third parties, or are managed for third parties.
AdCare revenue has grown steadily, more than doubling from 2006 to 2010, and, although fiscal 2011 is not yet completed, AdCare now appears to be on track for the biggest year-to-year revenue jump in the company’s history. Much of this is due to AdCare’s aggressive acquisition strategy, allowing them to spread their efficient operational model, and positioning them to serve one of the biggest demographic waves in American history, the aging boomer population. In addition, net income is now making its first intermittent forays into positive territory.
Besides being that rare beast, the emerging company that can offer a history of rising revenue along with on-the-cusp earnings, AdCare has set sail on a rising sea of industry growth. With improved healthcare virtually ensuring that many boomers will live well into their 80s and 90s, the demand for various forms of assisted living facilities and services is expected to explode to levels never before seen, providing a continually growing long term market.
But it’s important to remember that companies like AdCare represent an unusual combination of financials and market potential. It’s tempting to grab at developing companies that have a year or two of impressive revenues, or that seem to be oriented toward future markets, but very few companies exhibit five or more years of steadily rising revenues, together with earnings ready to break to the positive, together with a firm foundation in what can only be described as a tidal wave market that will stretch on for decades.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
There is a unique window of opportunity, and it doesn’t last long. As a company grows, drawing the attention of an increasing number of analysts, it becomes more a game of beating expectations. Eventually it’s no longer enough for the company to announce strong quarterly revenue and earnings numbers, the numbers have to beat analyst estimates. Also, when enough eyes are on the company, expectations can be built into the share price, allowing for a nasty tumble or major boost when earnings are announced. Everyone, including company executives, knows this, and companies do whatever they can to ensure that quarterly reports meet or beat expectations, out of concern that sudden well-publicized share price drops can send skittish investors away for good.
But, until that happens, while a company is still in that magic pre-blossom stage, an alert investor can line themselves up for a staggering short term gain. Even more desirable, of course, is when such a company is also positioned for continued long term growth, based upon efficient leveraging of an expanding market. Not every management team is smart enough to deal with the often hidden opportunities and challenges of market expansion. Companies can easily overextend themselves late in the cycle, generating an unsustainable financial burden just when the market turns south. If, however, management is able to stay ahead of the curve, taking advantage of low cost acquisitions before the boom, and understands how to grow and operate on increasing scales in advance of growing demand, the future holds few limits.
Take a look at AdCare Health Systems, an Ohio-based manager of senior living facilities. AdCare currently operates over 42 facilities in Ohio, Georgia, Alabama, Arkansas, and North Carolina, with new acquisitions continually being targeted. Facilities include independent living campuses, assisted living facilities, nursing homes, and dementia care facilities. The company also provides comprehensive home health care services. Facilities are either owned by AdCare, leased from third parties, or are managed for third parties.
AdCare revenue has grown steadily, more than doubling from 2006 to 2010, and, although fiscal 2011 is not yet completed, AdCare now appears to be on track for the biggest year-to-year revenue jump in the company’s history. Much of this is due to AdCare’s aggressive acquisition strategy, allowing them to spread their efficient operational model, and positioning them to serve one of the biggest demographic waves in American history, the aging boomer population. In addition, net income is now making its first intermittent forays into positive territory.
Besides being that rare beast, the emerging company that can offer a history of rising revenue along with on-the-cusp earnings, AdCare has set sail on a rising sea of industry growth. With improved healthcare virtually ensuring that many boomers will live well into their 80s and 90s, the demand for various forms of assisted living facilities and services is expected to explode to levels never before seen, providing a continually growing long term market.
But it’s important to remember that companies like AdCare represent an unusual combination of financials and market potential. It’s tempting to grab at developing companies that have a year or two of impressive revenues, or that seem to be oriented toward future markets, but very few companies exhibit five or more years of steadily rising revenues, together with earnings ready to break to the positive, together with a firm foundation in what can only be described as a tidal wave market that will stretch on for decades.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tuesday, December 27, 2011
Capstone Turbine Corp. (CPST) Receives Purchase Order from Large Nigerian Pharmaceutical Company
Capstone Turbine Corp., a leading producer of low-emission microturbine systems, today announced it has received an order for a C1000 and C200 for use at a large World Health Organization (WHO) certified Nigerian pharmaceutical company.
The pharmaceutical company will use Capstone’s microturbine systems to provide power and thermal energy for the manufacturing process. It will also improve plant efficiency while reducing its carbon footprint.
The order follows a recent meeting with a delegation of the Nigerian government and business leaders led by the U.S. Ambassador to Nigeria, in which discussions centered on how expanding the number of Capstone microturbines in Nigeria can benefit the country’s economy.
“The meeting was a big success as indicated by this order,” Jim Crouse, Capstone’s executive vice president of Sales and Marketing stated in the press release. “The meeting provided a tremendous opportunity for Capstone to support the U.S. government’s National Export Initiative and grow our sales throughout Nigeria, especially in the industrial and oil & gas markets.”
Capstone’s distribution partner Makon Power Systems Ltd. will head the installation, commissioning and aftermarket support for the system, and represents Makon’s second multiple unit order and first purchase of Capstone’s C200 and C1000 products.
“We expect several additional orders greater than a megawatt for industrial and oil & gas customers in Nigeria in the months to follow,” said Ademola Ajakaye, Makon’s chief operating officer.
For more information visit www.capstoneturbine.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The pharmaceutical company will use Capstone’s microturbine systems to provide power and thermal energy for the manufacturing process. It will also improve plant efficiency while reducing its carbon footprint.
The order follows a recent meeting with a delegation of the Nigerian government and business leaders led by the U.S. Ambassador to Nigeria, in which discussions centered on how expanding the number of Capstone microturbines in Nigeria can benefit the country’s economy.
“The meeting was a big success as indicated by this order,” Jim Crouse, Capstone’s executive vice president of Sales and Marketing stated in the press release. “The meeting provided a tremendous opportunity for Capstone to support the U.S. government’s National Export Initiative and grow our sales throughout Nigeria, especially in the industrial and oil & gas markets.”
Capstone’s distribution partner Makon Power Systems Ltd. will head the installation, commissioning and aftermarket support for the system, and represents Makon’s second multiple unit order and first purchase of Capstone’s C200 and C1000 products.
“We expect several additional orders greater than a megawatt for industrial and oil & gas customers in Nigeria in the months to follow,” said Ademola Ajakaye, Makon’s chief operating officer.
For more information visit www.capstoneturbine.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
AdCare Health Systems Inc. (ADK) Technical Analysis for Tuesday, December 27, 2011
ADK is coming down upon a support level that has held twice in the last few months. Both times the chart provided a nice bounce, and the indicators continue to drop hints of a potential true bottom for the stock price.
To view the video chart, visit the following link: http://www.missionir.com/videos.html
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
To view the video chart, visit the following link: http://www.missionir.com/videos.html
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
FluoroPharma Medical, Inc. (FPMI) Supported by a Stellar Scientific Advisory Board
FluoroPharma Medical, developer of advanced medical diagnostic imaging products, with a current focus on imaging agents for breakthrough positron emission tomography (PET) applications, obtains critical advice and guidance from a scientific advisory board made up of top experts in the fields of medical imagery and cardiology.
• Daniel Berman, MD, FACC, is Chief of Cardiac Imaging and Nuclear Cardiology at Cedars-Sinai Heart Center and Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles. A world-renowned expert in nuclear cardiology (the use of noninvasive nuclear imaging for the study of cardiovascular disease), he is one of the principal developers of techniques now widely used in nuclear cardiology.
• Peter Conti, MD, PhD, is Professor of Radiology, Biomedical Engineering, and Pharmacy at the University of Southern California, and has been Director of the USC PET Imaging Science Center since its inception in 1991. One of his major areas of research is in the development of molecular imaging agents for the diagnosis and monitoring of cancer metabolism and cell proliferation.
• Elazer Edelman, MD, PhD, is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at MIT, Professor of Medicine at Harvard Medical School, and a coronary care unit cardiologist at the Brigham and Women’s Hospital in Boston. He directs the Harvard-MIT Biomedical Engineering Center (BMEC), investigating ways to elucidate the fundamental biologic processes and mechanisms of disease.
• Heinrich Schelbert, MD, PhD, is Professor of Pharmacology and Radiological Sciences and a Chief of Cardiovascular Nuclear Medicine at the UCLA School of Medicine. He’s made seminal contributions related to cardiac PET imaging, including development of a radiotracer techniques used in non-invasive blood flow imaging, and is Editor-in-Chief of the Journal of Nuclear Medicine.
• Andrew Selwyn, MA, MD, PhD, is Professor of Medicine at Harvard Medical School and a Senior Physician and Associate Chief of the Cardiovascular Division (academic affairs) at Brigham and Women’s Hospital. He is a leading contributor to the research and clinical practice of interventional cardiology and biology of atherosclerosis.
For more information, see the company website at www.FluoroPharma.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
• Daniel Berman, MD, FACC, is Chief of Cardiac Imaging and Nuclear Cardiology at Cedars-Sinai Heart Center and Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles. A world-renowned expert in nuclear cardiology (the use of noninvasive nuclear imaging for the study of cardiovascular disease), he is one of the principal developers of techniques now widely used in nuclear cardiology.
• Peter Conti, MD, PhD, is Professor of Radiology, Biomedical Engineering, and Pharmacy at the University of Southern California, and has been Director of the USC PET Imaging Science Center since its inception in 1991. One of his major areas of research is in the development of molecular imaging agents for the diagnosis and monitoring of cancer metabolism and cell proliferation.
• Elazer Edelman, MD, PhD, is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at MIT, Professor of Medicine at Harvard Medical School, and a coronary care unit cardiologist at the Brigham and Women’s Hospital in Boston. He directs the Harvard-MIT Biomedical Engineering Center (BMEC), investigating ways to elucidate the fundamental biologic processes and mechanisms of disease.
• Heinrich Schelbert, MD, PhD, is Professor of Pharmacology and Radiological Sciences and a Chief of Cardiovascular Nuclear Medicine at the UCLA School of Medicine. He’s made seminal contributions related to cardiac PET imaging, including development of a radiotracer techniques used in non-invasive blood flow imaging, and is Editor-in-Chief of the Journal of Nuclear Medicine.
• Andrew Selwyn, MA, MD, PhD, is Professor of Medicine at Harvard Medical School and a Senior Physician and Associate Chief of the Cardiovascular Division (academic affairs) at Brigham and Women’s Hospital. He is a leading contributor to the research and clinical practice of interventional cardiology and biology of atherosclerosis.
For more information, see the company website at www.FluoroPharma.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Quantum Fuel Systems Technologies (QTWW) and SBE, Inc. Partner Up to Launch Next Generation Hybrid Electric Drive Systems
Quantum Fuel Systems Technologies and SBE, Inc. today announced the formation of a technology partnership between the two companies. SBE will be providing a novel integrated capacitor/bus structure design solution for Quantum power electronics for automotive applications, enabling higher performance, weight reduction, smaller packaging and total system cost savings.
“Quantum continues to optimize and improve the efficiencies of our advanced electric drive-train products. We expect the SBE integrated capacitor/bus structure to enable substantial packaging and performance advantages in our next generation electric and hybrid-electric drive systems,” stated Alan Niedzwiecki, CEO Quantum Technologies.
“SBE is pleased that Quantum Technologies is one of the first implementers of our advanced integrated capacitor/bus designs. We are proud to be partnering with a leading technology drivetrain provider like Quantum,” commented Ed Sawyer, President and CEO for SBE, Inc.
Jon Bereisa, Senior Technical Advisor for SBE, added, “The electrification of the automobile has successfully reached the technical feasibility stage today. Cost improvements are needed to reach the commercial viability stage for mass market acceptance. Cost must be attacked everywhere. The SBE power ring capacitor technology is a major enabler for power electronics design simplification, up-integration, and higher temperature operation to significantly drive down the cost while improving performance.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“Quantum continues to optimize and improve the efficiencies of our advanced electric drive-train products. We expect the SBE integrated capacitor/bus structure to enable substantial packaging and performance advantages in our next generation electric and hybrid-electric drive systems,” stated Alan Niedzwiecki, CEO Quantum Technologies.
“SBE is pleased that Quantum Technologies is one of the first implementers of our advanced integrated capacitor/bus designs. We are proud to be partnering with a leading technology drivetrain provider like Quantum,” commented Ed Sawyer, President and CEO for SBE, Inc.
Jon Bereisa, Senior Technical Advisor for SBE, added, “The electrification of the automobile has successfully reached the technical feasibility stage today. Cost improvements are needed to reach the commercial viability stage for mass market acceptance. Cost must be attacked everywhere. The SBE power ring capacitor technology is a major enabler for power electronics design simplification, up-integration, and higher temperature operation to significantly drive down the cost while improving performance.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Friday, December 23, 2011
Quantum Fuel Systems Technologies Worldwide (QTWW) Enters Strategic Relationship With Major Wind Turbine Manufacture To Finance and Develop Wind Farms Globally
Quantum Fuel Systems Technologies Worldwide, Inc, a fully integrated alternative energy company, in conjunction with their wholly-owned subsidiary Schneider Power, Inc, one of Canada’s premier renewable energy companies, today announced a new strategic agreement between Schneider’s wholly-owned subsidiary Trout Creek Wind Power and a major global wind turbine manufacturer for the financing and developing of wind farms in North America. The details of the deal include the manufacture will provide a maximum of CDN $24 Million dollars for finance of the construction of the generation facility and the Company will utilize the manufacturers wind turbines at the 10 MW Trout Creek Wind Farm in Ontario, Canada. Both parties anticipate closure on the deal by December 31, 2012 and agree to meet the 50% local content requirement from the Ontario Government.
“We are excited about this relationship as it provides an opportunity for us to finance the Trout Creek and potentially other wind farms while retaining 100% ownership in each project. We are hopeful that the Trout Creek agreement will be the first among a broader strategic relationship aimed at financing and developing Schneider Power’s global portfolio of 1,000 MW of wind farms,” said Alan Niedzwiecki, Quantum’s CEO in a press release.
Schneider Power has successfully completed the required wind studies to finalize the wind farm and the final environmental permitting is underway. The construction of the renewable energy generation facility is expected to be completed on schedule. Further the company anticipates that Trout Farm will produce electricity for the Ontario Power Authority as authorized in a 20-year purchase agreement with the Ontario Government’s Feed-In-Tariff program at a rate of $135/MWH starting in the fall of 2013. The local utility Hydro One Networks, Inc will help link the Wind Farm to an existing high voltage transmission line near the property.
In Canada, Schneider Power currently operates wind farms and has a significant development portfolio of potential renewable power facilities in excess of 1,000 MW. Across North America, the company evaluates, designs ,builds, owns and operates some of the most advanced renewable energy generation projects.
For more information, please visit www.qtwww.com or www.schneiderpower.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“We are excited about this relationship as it provides an opportunity for us to finance the Trout Creek and potentially other wind farms while retaining 100% ownership in each project. We are hopeful that the Trout Creek agreement will be the first among a broader strategic relationship aimed at financing and developing Schneider Power’s global portfolio of 1,000 MW of wind farms,” said Alan Niedzwiecki, Quantum’s CEO in a press release.
Schneider Power has successfully completed the required wind studies to finalize the wind farm and the final environmental permitting is underway. The construction of the renewable energy generation facility is expected to be completed on schedule. Further the company anticipates that Trout Farm will produce electricity for the Ontario Power Authority as authorized in a 20-year purchase agreement with the Ontario Government’s Feed-In-Tariff program at a rate of $135/MWH starting in the fall of 2013. The local utility Hydro One Networks, Inc will help link the Wind Farm to an existing high voltage transmission line near the property.
In Canada, Schneider Power currently operates wind farms and has a significant development portfolio of potential renewable power facilities in excess of 1,000 MW. Across North America, the company evaluates, designs ,builds, owns and operates some of the most advanced renewable energy generation projects.
For more information, please visit www.qtwww.com or www.schneiderpower.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
China Direct Industries, Inc. (CDII) FY11 Financials Report Shows Solid Growth, Positive Leading Indicators in Fundamentals
Today, China Direct, a veritable clearinghouse for investment capital interests and management logistics based in the US, which serves the small- to mid-sized business sector of the PRC and produces/distributes to both markets (largely industrial products), reported excellent financials for FY11 (period ending Sept. 30).
Let’s take a look at a quick breakdown of the salient data points from the report:
Revenue up 66.6% to $187.8M from FY10
Gross Profits up 171.1% to $19.5M over FY10 data – GP Margins also up 63% (to 10.4%)
Net Income of $9.3M compared to a $3.2M loss in FY10
Diluted EPS of $0.25 compared to a loss of $0.11 per share in FY10
Total Assets of $116M, up 21% over FY10
Shareholder Equity of $68M (up 35.5%) on 40.4M (31.7M in FY10) shares outstanding
Cash and Cash Equiv. up 24.8% to $12.6M and Prepaid Expense up 67.4% to $14.4M
Working Capital up 46.9% to $44.5M
All around a huge upswing for CDII as this ambitious Deerfield Beach, Florida headquartered continent spanner becomes an increasingly dominant hub for nurturing various entities and business solutions to fruition within the PRC.
Growth across all business segments in FY11 shows solid evolution of end market cohesion, with revenue from the Ruiming Magnesium acquisition, the consulting segment and international commodities businesses leading the charge. Magnesium segment hit $99.9M, up 95.3% on strong demand and high volume (up 68.2%, or 36,637 metric tons) bolstered by an increase in the average sale price (up 15.1% to $2,703/ton).
The basic materials segment saw similar dynamics with revenue up 17.2% to $68.9M largely on the strength iron ore from the Company’s US-based industrial commodities business. The consulting segment did quite well, bringing in total revenues of $19M, up a whopping 578.6% on fees earned via two new big clients.
The abundant forward momentum generated across the entire operating environment in FY11 is set to be exploited fully by CDII and despite some cyclical softening of magnesium demand late in the year the Company went into FY12 with strong prices and indicators. Plans to utilize cleaner and more efficient waste gas, combined with strategic magnesium acquisitions should really push operations to a whole new level for CDII in this segment and projected tightening of Chinese supply should accelerate things significantly.
Chairman and CEO of CDII, Dr. James Wang, commented on the bold return of the Company to profitability in FY11, and underscored the potential of consolidation in the magnesium segment, as well as the Company’s successful expansion efforts in North and South America. Sourcing iron ore from Mexico into China, crystallizing price/logistical dynamics in the magnesium segment and due diligence fostering a stronger presence in Bolivia/Chile in order to meet market demand by growing the Company’s commodities business well through 2012, all are seen as contributing factors to a positive forward outlook. With the current business environment for publicly US-traded Chinese companies lighting brushfires of production across the operational landscape, CDII is positioning for strong growth in fundamentals as the consulting business really starts to heat up.
For more information on the financials report, or on China Direct Industries, Inc., please visit the Company’s website at: www.cdii.net
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Let’s take a look at a quick breakdown of the salient data points from the report:
Revenue up 66.6% to $187.8M from FY10
Gross Profits up 171.1% to $19.5M over FY10 data – GP Margins also up 63% (to 10.4%)
Net Income of $9.3M compared to a $3.2M loss in FY10
Diluted EPS of $0.25 compared to a loss of $0.11 per share in FY10
Total Assets of $116M, up 21% over FY10
Shareholder Equity of $68M (up 35.5%) on 40.4M (31.7M in FY10) shares outstanding
Cash and Cash Equiv. up 24.8% to $12.6M and Prepaid Expense up 67.4% to $14.4M
Working Capital up 46.9% to $44.5M
All around a huge upswing for CDII as this ambitious Deerfield Beach, Florida headquartered continent spanner becomes an increasingly dominant hub for nurturing various entities and business solutions to fruition within the PRC.
Growth across all business segments in FY11 shows solid evolution of end market cohesion, with revenue from the Ruiming Magnesium acquisition, the consulting segment and international commodities businesses leading the charge. Magnesium segment hit $99.9M, up 95.3% on strong demand and high volume (up 68.2%, or 36,637 metric tons) bolstered by an increase in the average sale price (up 15.1% to $2,703/ton).
The basic materials segment saw similar dynamics with revenue up 17.2% to $68.9M largely on the strength iron ore from the Company’s US-based industrial commodities business. The consulting segment did quite well, bringing in total revenues of $19M, up a whopping 578.6% on fees earned via two new big clients.
The abundant forward momentum generated across the entire operating environment in FY11 is set to be exploited fully by CDII and despite some cyclical softening of magnesium demand late in the year the Company went into FY12 with strong prices and indicators. Plans to utilize cleaner and more efficient waste gas, combined with strategic magnesium acquisitions should really push operations to a whole new level for CDII in this segment and projected tightening of Chinese supply should accelerate things significantly.
Chairman and CEO of CDII, Dr. James Wang, commented on the bold return of the Company to profitability in FY11, and underscored the potential of consolidation in the magnesium segment, as well as the Company’s successful expansion efforts in North and South America. Sourcing iron ore from Mexico into China, crystallizing price/logistical dynamics in the magnesium segment and due diligence fostering a stronger presence in Bolivia/Chile in order to meet market demand by growing the Company’s commodities business well through 2012, all are seen as contributing factors to a positive forward outlook. With the current business environment for publicly US-traded Chinese companies lighting brushfires of production across the operational landscape, CDII is positioning for strong growth in fundamentals as the consulting business really starts to heat up.
For more information on the financials report, or on China Direct Industries, Inc., please visit the Company’s website at: www.cdii.net
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Genesis Rehab Services extends Market Presence through Partnership with AdCare Health Systems (ADK), creates New Job Opportunities
AdCare Health Systems Inc. has established a partnership with Genesis Rehab Services (GRS), a provider of physical, occupational, speech and respiratory therapy services in the long-term care industry, expanding GRS’s presence in Oklahoma and Arkansas and creating new jobs opportunities.
AdCare currently manages 31 facilities, 23 of which are skilled nursing centers, seven assisted living facilities, and one independent senior living community. Effective Jan. 1, 2012, GRS will operate and staff 13 rehab gyms for AdCare, which develops, owns and manages nursing homes and assisted living facilities.
“Genesis Rehab Services has a solid reputation in the industry,” Judi Pritchard, vice president for Rehabilitation at AdCare stated in the press release. “We know that the investments they make in their staff, including their focus on continuing education and strong clinical support, will ensure that our patients and residents receive the best possible rehabilitation therapy services available.”
GRS currently has more than 1,000 locations in 27 states and the District of Columbia, and anticipates steady growth in new and existing markets in 2012.
The partnership creates new job opportunities for the Enid and Grove areas of Oklahoma as well as in the Bentonville, Ft. Smith, and Stamps communities of Arkansas, where GRS is hiring licensed physical therapists, physical therapist assistants, occupational therapists, certified occupational therapy assistants, speech-language pathologists, and rehab managers across both states.
For more information visit www.adcarehealth.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
AdCare currently manages 31 facilities, 23 of which are skilled nursing centers, seven assisted living facilities, and one independent senior living community. Effective Jan. 1, 2012, GRS will operate and staff 13 rehab gyms for AdCare, which develops, owns and manages nursing homes and assisted living facilities.
“Genesis Rehab Services has a solid reputation in the industry,” Judi Pritchard, vice president for Rehabilitation at AdCare stated in the press release. “We know that the investments they make in their staff, including their focus on continuing education and strong clinical support, will ensure that our patients and residents receive the best possible rehabilitation therapy services available.”
GRS currently has more than 1,000 locations in 27 states and the District of Columbia, and anticipates steady growth in new and existing markets in 2012.
The partnership creates new job opportunities for the Enid and Grove areas of Oklahoma as well as in the Bentonville, Ft. Smith, and Stamps communities of Arkansas, where GRS is hiring licensed physical therapists, physical therapist assistants, occupational therapists, certified occupational therapy assistants, speech-language pathologists, and rehab managers across both states.
For more information visit www.adcarehealth.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Granite City Food & Brewery (GCFB) Acquires Assets of Miami-Based Cadillac Ranch Restaurant
Today, Granite City Food & Brewery Ltd. announced that it completed the purchase of assets belonging to the Cadillac Ranch All American Bar & Grill restaurant in Miami, Florida. The Miami restaurant is located in the Palms Town & Country Mall.
Granite City previously announced that it purchased the assets of the Cadillac Ranch restaurant at the Mall of America in Bloomington, Minnesota. To date, the aggregate purchase price totals $2.8 million, including the $1.4 million paid in November 2011 for the assets at the Mall of America. The companies have a master asset purchase agreement that allows for the purchase of the assets of up to five additional Cadillac Ranch restaurants.
Since Granite City’s May 2011 receipt of debt financing from Fifth Third Bank, the company has developed plans to enhance revenue at existing Cadillac Ranch stores and also develop new stores, such as the recently announced Troy, Michigan location. That location is scheduled to open in early 2012.
Granite City Food & Brewery is a modern American restaurant and brewery. The restaurant serves food made fresh on site using high quality ingredients. Extensive menu features moderately priced favorites served in generous portions. It also offers an award-winning signature line of craft beers. Granite City Food & Brewery Ltd. opened its first restaurant in St. Cloud, Minnesota in 1999 and now operates 28 restaurants in 12 states.
Please visit www.gcfb.net for more information.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Granite City previously announced that it purchased the assets of the Cadillac Ranch restaurant at the Mall of America in Bloomington, Minnesota. To date, the aggregate purchase price totals $2.8 million, including the $1.4 million paid in November 2011 for the assets at the Mall of America. The companies have a master asset purchase agreement that allows for the purchase of the assets of up to five additional Cadillac Ranch restaurants.
Since Granite City’s May 2011 receipt of debt financing from Fifth Third Bank, the company has developed plans to enhance revenue at existing Cadillac Ranch stores and also develop new stores, such as the recently announced Troy, Michigan location. That location is scheduled to open in early 2012.
Granite City Food & Brewery is a modern American restaurant and brewery. The restaurant serves food made fresh on site using high quality ingredients. Extensive menu features moderately priced favorites served in generous portions. It also offers an award-winning signature line of craft beers. Granite City Food & Brewery Ltd. opened its first restaurant in St. Cloud, Minnesota in 1999 and now operates 28 restaurants in 12 states.
Please visit www.gcfb.net for more information.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Albany Molecular Research, Inc. (AMRI) To Streamline Operations
Albany Molecular Research, reflecting the ongoing challenges of the global economy, announced today a series of cost saving actions for 2012, including a reduction in the company’s workforce. The moves are designed to improve AMRI’s overall cost competiveness and increase cash flow generation. The workforce reductions are primarily aimed at U.S. operations, and are in line with earlier announced reductions in the company’s internal R&D activities. The goal is to generate a total annual savings of approximately $10-$11 million. Although savings will begin to be recognized in the first quarter of 2012, AMRI expects to incur a pre-tax restructuring charge in the fourth quarter of approximately $5-$6 million associated with a lease termination and employee severance costs.
AMRI has also filed a shelf registration statement with the SEC, intended to provide the company with flexibility to raise funds from the offering of its securities. The company may occasionally offer its common stock, preferred stock, and warrants, up to an aggregate public offering price of $50 million.
AMRI’s President and CEO, Thomas E. D’Ambra, spoke of the move: “As we stated in our announcement in November, we are committed to taking the necessary actions to reduce the Company’s operating expenses to focus on our core contract research and manufacturing business and to ensure profitability. These actions will place AMRI in a more cost-competitive position while ensuring we continue to provide the highest quality service to our clients. We are moving quickly on these carefully considered actions and expect them to positively impact cash flow during the next year. Although our outlook for growth in outsourced contract services by global pharmaceutical companies remains positive, as evidenced by our recent strategic deals, we continue to evaluate our global infrastructure for additional opportunities to streamline our operations and reduce cost.”
AMRI is a global contract research and manufacturing organization that provides customers with integrated services for the development of pharmaceutical products and the manufacturing of API and drug product for existing and experimental new drugs.
For additional information, visit the company’s website at www.AMRIGlobal.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
AMRI has also filed a shelf registration statement with the SEC, intended to provide the company with flexibility to raise funds from the offering of its securities. The company may occasionally offer its common stock, preferred stock, and warrants, up to an aggregate public offering price of $50 million.
AMRI’s President and CEO, Thomas E. D’Ambra, spoke of the move: “As we stated in our announcement in November, we are committed to taking the necessary actions to reduce the Company’s operating expenses to focus on our core contract research and manufacturing business and to ensure profitability. These actions will place AMRI in a more cost-competitive position while ensuring we continue to provide the highest quality service to our clients. We are moving quickly on these carefully considered actions and expect them to positively impact cash flow during the next year. Although our outlook for growth in outsourced contract services by global pharmaceutical companies remains positive, as evidenced by our recent strategic deals, we continue to evaluate our global infrastructure for additional opportunities to streamline our operations and reduce cost.”
AMRI is a global contract research and manufacturing organization that provides customers with integrated services for the development of pharmaceutical products and the manufacturing of API and drug product for existing and experimental new drugs.
For additional information, visit the company’s website at www.AMRIGlobal.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Helix BioPharma Corp (HBP) files for Clinical Trial Application in Germany and UK for Approval of Phase III Efficacy Trial
Helix BioPharma Corp., a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, has filed a clinical trial application (CTA) in both Germany and the United Kingdom, with the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) and the Medicines and Healthcare Regulatory Authority (MHRA) respectively. The company is seeking approval to perform its planned European phase III efficacy trial of Topical Interferon Alpha-2b in patients with low-grade cervical lesions.
Topical Interferon Alpha-2b is the company’s most advanced product in development. By incorporating Helix’s proprietary Biphasix™ drug delivery technology, Topical Interferon Alpha-2b is designed to offer a superior method of delivering interferon alpha-2b therapeutically to HPV-infected tissues. The product is designed for patients with low-grade cervical lesions for which there is no available pharmaceutical therapy in the current market.
“This is a significant step for Helix. We are seeking approval to conduct what we intend to be a second, confirmatory efficacy trial of Topical Interferon Alpha-2b in patients with low-grade cervical lesions, to complement and parallel our recently approved U.S. phase II/III efficacy trial,” John Docherty, president of Helix stated in the press release. “Together, these two pivotal efficacy trials, if successful, are intended to support U.S. and European marketing authorizations for the product for this indication.”
Helix selected Germany for filing its CTA due to the fact that it has a history of conducting clinical studies with the product in Germany in the past. In addition, both Germany and the UK have a large population from which to recruit prospective patients.
The CTA process is preceded by a two-week initial screening process followed by a 30-day CTA review for each jurisdiction. The proposed 12-month phase III trial is planned to be a randomized, double-blind study of Topical Interferon Alpha-2b. The company will enroll approximately 492 female patients who will receive a dose regimen identical to the recently completed phase II pharmacokinetic study of Topical Interferon Alpha-2b.
Helix said that contingent on their success, results of its U.S. phase II/III trial and European phase III trial will be submitted together in order to seek U.S. and European marketing authorizations for the product for this indication.
However, Helix needs additional funding and a strategic partner support before commencing this trial, and as such, the company cannot offer an estimated timeline for start or completion of this trial.
For more information visit www.helixbiopharma.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Topical Interferon Alpha-2b is the company’s most advanced product in development. By incorporating Helix’s proprietary Biphasix™ drug delivery technology, Topical Interferon Alpha-2b is designed to offer a superior method of delivering interferon alpha-2b therapeutically to HPV-infected tissues. The product is designed for patients with low-grade cervical lesions for which there is no available pharmaceutical therapy in the current market.
“This is a significant step for Helix. We are seeking approval to conduct what we intend to be a second, confirmatory efficacy trial of Topical Interferon Alpha-2b in patients with low-grade cervical lesions, to complement and parallel our recently approved U.S. phase II/III efficacy trial,” John Docherty, president of Helix stated in the press release. “Together, these two pivotal efficacy trials, if successful, are intended to support U.S. and European marketing authorizations for the product for this indication.”
Helix selected Germany for filing its CTA due to the fact that it has a history of conducting clinical studies with the product in Germany in the past. In addition, both Germany and the UK have a large population from which to recruit prospective patients.
The CTA process is preceded by a two-week initial screening process followed by a 30-day CTA review for each jurisdiction. The proposed 12-month phase III trial is planned to be a randomized, double-blind study of Topical Interferon Alpha-2b. The company will enroll approximately 492 female patients who will receive a dose regimen identical to the recently completed phase II pharmacokinetic study of Topical Interferon Alpha-2b.
Helix said that contingent on their success, results of its U.S. phase II/III trial and European phase III trial will be submitted together in order to seek U.S. and European marketing authorizations for the product for this indication.
However, Helix needs additional funding and a strategic partner support before commencing this trial, and as such, the company cannot offer an estimated timeline for start or completion of this trial.
For more information visit www.helixbiopharma.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Harvest Natural Resources, Inc. (HNR) Reports On International Oil And Gas Exploration Activities
Harvest Natural Resources, Inc. issued an operations update on the company’s international oil and gas activities. The company is active in various properties in Asia and the Middle East.
Harvest Natural Resources, Inc. started drilling an exploratory well on Qarn Alam Block 64 in Oman. The Al Ghubar North–A well is the second of a two well program designed to test the hydrocarbon potential of this block. The company reported that the well is being drilled by the Rig #113 drilling unit owned by MB Petroleum Services LLC.
Harvest Natural Resources, Inc. is testing the potential of the Al Ghubar North structure, which consists of the Barik, Miqrat and Amin reservoirs. The company estimates the exploratory success of this well at 23%.
Harvest Natural Resources, Inc. owns an 80% working interest in the Al Ghubar North–A well and will drill the well to a total vertical depth of 10,300 feet at a cost of $8.1 million.
Harvest Natural Resources, Inc. is also active on the Budong-Budong Block located in West Sulawesi, Indonesia. The company reported that the KD-1 exploration well has reached at total depth of approximately 14,400 feet and is being evaluated by the company.
For more information on the company, go to http://www.harvestnr.com/
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Harvest Natural Resources, Inc. started drilling an exploratory well on Qarn Alam Block 64 in Oman. The Al Ghubar North–A well is the second of a two well program designed to test the hydrocarbon potential of this block. The company reported that the well is being drilled by the Rig #113 drilling unit owned by MB Petroleum Services LLC.
Harvest Natural Resources, Inc. is testing the potential of the Al Ghubar North structure, which consists of the Barik, Miqrat and Amin reservoirs. The company estimates the exploratory success of this well at 23%.
Harvest Natural Resources, Inc. owns an 80% working interest in the Al Ghubar North–A well and will drill the well to a total vertical depth of 10,300 feet at a cost of $8.1 million.
Harvest Natural Resources, Inc. is also active on the Budong-Budong Block located in West Sulawesi, Indonesia. The company reported that the KD-1 exploration well has reached at total depth of approximately 14,400 feet and is being evaluated by the company.
For more information on the company, go to http://www.harvestnr.com/
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, December 22, 2011
Capstone Turbine Corp. (CPST) Sells Three C1000 MicroTurbines to Independent Oil & Gas Producer for Production of Electricity
Capstone Turbine, the world’s leading clean technology manufacturer of microturbine energy systems, today announced that they have inked a deal for three Capstone C1000 microturbines that will provide three megawatts of clean power to an Independent Oil & Gas producer working in the Eagle Ford Shale play. Installation and commissioning of the multiple megawatt microturbines should be completed in 90 days. Capstone’s distributor, Horizon Power Systems, expects that the customer will order additional C1000 Power Packages in 2012 to continue to provide power for the central processing facility and metering stations in the remote areas of the Eagle Ford Shale play.
“The adoption and deployment of Capstone microturbines continues to accelerate in the worldwide oil & gas markets,” said Jim Crouse, Capstone’s Executive Vice President of Sales and Marketing in a press release. “Specifically, we continue to see very strong order activity in Russia for associated gas applications and in the Marcellus and Eagle Ford shale plays here in the U.S.”
Capstone’s technology creates reliable power using unprocessed wellhead gas to generate continuous load-following power. The microturbines work without the use of oil, lubricants, coolants, other hazardous materials or even water thus eliminating the need for transporting, storage and costly hazmat spill/leakage issues associated with engine gensets. In the Eagle Ford Shale play, the power created will provide clean and green electricity for the onsite equipment, including heaters, pump motors, circulation pumps and distribution panels.
“It’s great to get another significant oil and gas producer to adopt Capstone’s cutting edge turbine technology,” said Sam Henry, Horizon Power Systems (Pumps & Service) President in the press release. “They, like other Eagle Ford producers, are understanding the high reliability and low emission benefits of the Capstone family of products and the important role microturbines can play in ensuring around-the-clock energy production.”
As the first to market with a commercially viable microturbine energy product, Capstone Turbine has shipped over 6,000 systems worldwide. Additionally, this is the fourth Independent Oil & Gas provider to use Capstone technology in the U.S. shale market.
For more information, please visit www.capstoneturbine.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“The adoption and deployment of Capstone microturbines continues to accelerate in the worldwide oil & gas markets,” said Jim Crouse, Capstone’s Executive Vice President of Sales and Marketing in a press release. “Specifically, we continue to see very strong order activity in Russia for associated gas applications and in the Marcellus and Eagle Ford shale plays here in the U.S.”
Capstone’s technology creates reliable power using unprocessed wellhead gas to generate continuous load-following power. The microturbines work without the use of oil, lubricants, coolants, other hazardous materials or even water thus eliminating the need for transporting, storage and costly hazmat spill/leakage issues associated with engine gensets. In the Eagle Ford Shale play, the power created will provide clean and green electricity for the onsite equipment, including heaters, pump motors, circulation pumps and distribution panels.
“It’s great to get another significant oil and gas producer to adopt Capstone’s cutting edge turbine technology,” said Sam Henry, Horizon Power Systems (Pumps & Service) President in the press release. “They, like other Eagle Ford producers, are understanding the high reliability and low emission benefits of the Capstone family of products and the important role microturbines can play in ensuring around-the-clock energy production.”
As the first to market with a commercially viable microturbine energy product, Capstone Turbine has shipped over 6,000 systems worldwide. Additionally, this is the fourth Independent Oil & Gas provider to use Capstone technology in the U.S. shale market.
For more information, please visit www.capstoneturbine.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
AdCare Health Systems, Inc. (ADK) Positioned for Strong, Consistent Growth
AdCare Health Systems, Inc. is an expanding national leader in the development, ownership, and management of assisted living facilities, nursing homes and retirement communities. The company’s 3,200 employees provide high-quality care for patients and residents residing in the 42 facilities that it operates with a total of approximately 3,700 beds/units in service.
As a result of better health management and treatments allowing people to live longer, the Census Bureau projects that the population aged 85 and over could grow from 5.7 million in 2008 to 19 million by 2050. AdCare has been successfully pursuing an aggressive M&A growth strategy to bolster its portfolio during a depressed economic climate to capitalize on the imminent demand for senior care over the coming decades.
The fragmented skilled nursing market presents significant consolidation and acquisition opportunities to well-established providers like AdCare. With approximately 16,000 facilities currently in operation, no single provider has a market share of more than a few percent. Leveraging its seasoned senior management team’s substantial senior living, healthcare, and real estate industry experience, the company is focused on advancing its strategic business plan to operate a much larger enterprise.
Since inception, AdCare’s mission has been to provide the highest quality healthcare services to the elderly. With nine straight years of record revenue growth, the company has proven its ability to deliver high-quality care and strong operational efficiency. AdCare is well positioned to continue growing rapidly, both organically and via acquisitions, as industry trends and burgeoning opportunities across the U.S. increase the demand for long-term care.
Key Investment Highlights
Aggressive M&A Growth Strategy to Capitalize on Expanding $226 Billion Market
Ladenburg Thalmann Analysts Recently Issued “Buy” Rating and $7.50 Price Target
More than 25% of Outstanding Shares Owned by Management Team
Well Established with Nine Straight Years of Record Revenue Growth
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
As a result of better health management and treatments allowing people to live longer, the Census Bureau projects that the population aged 85 and over could grow from 5.7 million in 2008 to 19 million by 2050. AdCare has been successfully pursuing an aggressive M&A growth strategy to bolster its portfolio during a depressed economic climate to capitalize on the imminent demand for senior care over the coming decades.
The fragmented skilled nursing market presents significant consolidation and acquisition opportunities to well-established providers like AdCare. With approximately 16,000 facilities currently in operation, no single provider has a market share of more than a few percent. Leveraging its seasoned senior management team’s substantial senior living, healthcare, and real estate industry experience, the company is focused on advancing its strategic business plan to operate a much larger enterprise.
Since inception, AdCare’s mission has been to provide the highest quality healthcare services to the elderly. With nine straight years of record revenue growth, the company has proven its ability to deliver high-quality care and strong operational efficiency. AdCare is well positioned to continue growing rapidly, both organically and via acquisitions, as industry trends and burgeoning opportunities across the U.S. increase the demand for long-term care.
Key Investment Highlights
Aggressive M&A Growth Strategy to Capitalize on Expanding $226 Billion Market
Ladenburg Thalmann Analysts Recently Issued “Buy” Rating and $7.50 Price Target
More than 25% of Outstanding Shares Owned by Management Team
Well Established with Nine Straight Years of Record Revenue Growth
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Rackwise, Inc. (RACK) Lands Master License to Deploy Data Center Management Software at All Intel Data Centers Worldwide
San Francisco based Rackwise, Inc., provider of software for the rapidly growing market of Data Center Infrastructure Management (DCIM), has executed a series of agreements with Intel Corporation to affect a master license for the intended deployment of Rackwise’s Data Center Management (DCM) software in all Intel data centers around the world. Implementation and deployment of the DCM software is expected to commence in the first quarter of 2012, with deployment to 6 Intel data centers in various regions globally. Second phase deployment will be to the remaining 60 Intel data centers worldwide. Specifically, the agreement calls for a technology collaboration to embed Intel DCM software into the Rackwise DCM product, effectively giving users real time data monitoring and reporting capabilities at unparalleled granular levels.
This major DCIM implementation will include an evaluation and feedback agreement related to Rackwise’s next generation DCIM software solutions, which will initially be available only to Intel, but will subsequently be offered to all customers. The initial deployment will encompass a substantial amount of equipment comprising Intel information technology assets, and will include asset modeling, power mapping, cooling, network availability, and multiple virtualized product instances, data replication across regions, proximity load balancing, and initial data migration from currently installed DCIM tools.
Rackwise CEO, Guy A. Archbold, spoke of the landmark agreement: “We are extremely pleased and proud to join in collaboration with Intel®, a leader in worldwide IT and computing innovation, to develop and introduce this ground-breaking capability for the Data Center Infrastructure Management market. Integrating device level data aggregation exclusively within our asset visualization, modeling, and analytics functions will provide data center and infrastructure technology professionals powerful, state-of-the-art tools for real-time data management to maximize operational efficiencies and economic benefits.”
Intel’s Director of Data Center Solutions, Jeff Klaus, added, “The Intel® Data Center Manager combined with RACKWISE® DCM helps provide data center managers and executives extensive visibility into device level energy usage and thermal data which will enhance capacity planning, forecasting, performance monitoring and energy management for significant operational savings. RACKWISE® DCM ’s extensive visualization, reporting and analytics platform combined with information from Intel® DCM will give data center personnel an unprecedented level of intelligent access and control over the physical and virtual assets within the data center.”
For additional information on Rackwise, visit the company’s website at www.Rackwise.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
This major DCIM implementation will include an evaluation and feedback agreement related to Rackwise’s next generation DCIM software solutions, which will initially be available only to Intel, but will subsequently be offered to all customers. The initial deployment will encompass a substantial amount of equipment comprising Intel information technology assets, and will include asset modeling, power mapping, cooling, network availability, and multiple virtualized product instances, data replication across regions, proximity load balancing, and initial data migration from currently installed DCIM tools.
Rackwise CEO, Guy A. Archbold, spoke of the landmark agreement: “We are extremely pleased and proud to join in collaboration with Intel®, a leader in worldwide IT and computing innovation, to develop and introduce this ground-breaking capability for the Data Center Infrastructure Management market. Integrating device level data aggregation exclusively within our asset visualization, modeling, and analytics functions will provide data center and infrastructure technology professionals powerful, state-of-the-art tools for real-time data management to maximize operational efficiencies and economic benefits.”
Intel’s Director of Data Center Solutions, Jeff Klaus, added, “The Intel® Data Center Manager combined with RACKWISE® DCM helps provide data center managers and executives extensive visibility into device level energy usage and thermal data which will enhance capacity planning, forecasting, performance monitoring and energy management for significant operational savings. RACKWISE® DCM ’s extensive visualization, reporting and analytics platform combined with information from Intel® DCM will give data center personnel an unprecedented level of intelligent access and control over the physical and virtual assets within the data center.”
For additional information on Rackwise, visit the company’s website at www.Rackwise.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, December 21, 2011
China TechFaith Wireless Communication Technology Ltd. (CNTF) Purchases Land for New R&D Facility
Today, China TechFaith Wireless Communication Technology Ltd. announced that the Shenyang Government has granted approval for the company to acquire approximately 11.5 acres in Shenyang City’s Shenbei New District. TechFaith will use the property to construct a new facility, which will include integrated R&D, sales and distribution. The land contract is valued at approximately $2.3 million US dollars.
The new facility is part of a broader, major joint venture development project between TechFaith and the Shenyang PuHe New Town Administration Committee. TechFaith expects to invest approximately $31.5 million over the next three years; PuHe will invest approximately $6.3 million in the joint venture development project and will also provide up to $1.6 million to TechFaith as an investment incentive. The joint venture entity will be 16.7% owned by PuHe, with the remaining owned by TechFatih.
The capital of the Liaoning Province and the largest city in Northeastern China, Sheyang is also one of the country’s premier centers for high technology and industrial development. Sheyang also provides the backdrop for many of the China’s top universities.
Mr. Defu Dong, Chairman and CEO of TechFaith, commented, “Being able to locate an integrated facility in such a prominent high technology and industrial center will give TechFaith an advantage when working with customers and partners, hiring top R&D and sales talent, and will enhance our profile with new customers. Importantly, our joint venture will allow us to expand our capabilities while remaining financially conservative. This means we will have the benefits of our expanded capacity when the industry resumes the growth portion of the current cycle, while continuing to maintain the strong balance sheet needed to support our ongoing growth and success.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The new facility is part of a broader, major joint venture development project between TechFaith and the Shenyang PuHe New Town Administration Committee. TechFaith expects to invest approximately $31.5 million over the next three years; PuHe will invest approximately $6.3 million in the joint venture development project and will also provide up to $1.6 million to TechFaith as an investment incentive. The joint venture entity will be 16.7% owned by PuHe, with the remaining owned by TechFatih.
The capital of the Liaoning Province and the largest city in Northeastern China, Sheyang is also one of the country’s premier centers for high technology and industrial development. Sheyang also provides the backdrop for many of the China’s top universities.
Mr. Defu Dong, Chairman and CEO of TechFaith, commented, “Being able to locate an integrated facility in such a prominent high technology and industrial center will give TechFaith an advantage when working with customers and partners, hiring top R&D and sales talent, and will enhance our profile with new customers. Importantly, our joint venture will allow us to expand our capabilities while remaining financially conservative. This means we will have the benefits of our expanded capacity when the industry resumes the growth portion of the current cycle, while continuing to maintain the strong balance sheet needed to support our ongoing growth and success.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Repligen Corp. (RGEN) Submits New Drug Application for Powerful MRI Imaging Agent SecreFlo™
Today, Repligen Corp., already leading with a strong presence in critical components used in the manufacture of biologic drugs, announced they are taking development of their SecreFlo™ hormone, designed for use as an imaging enhancer for diagnosing pancreatic diseases, to the next level with the submission of an NDA (new drug application).
SecreFlo (RG1068, synthetic human secretin) is a powerful tool for vastly improving detection rates of abnormalities in the ducts of the pancreas during MRI examination for pancreatitis, which is characterized by such structural abnormalities and related serious abdominal pain. Increased sensitivity, image quality and the overall ability to have total visualization of the entire length of the pancreatic ducts, was validated for SecreFlo in the pivotal Phase 3 study, where MRI examination using the agent generated statistical improvements across all these key factors.
SecreFlo helps to stimulate fluid secretion in the pancreas, thus making visualization by MRI more effective. The multi-center, baseline controlled and single dose Phase 3 study of SecreFlo included 258 patients enrolled via 23 clinical sites throughout the U.S. and Canada. Evaluation for 10 pre-specified abnormalities against image quality, overall visualization and diagnostic capability data points was solid. Review by the team of three independent radiologists of the radiographic image data overturned the original analysis soundly, which was determined to be flawed and therefore inconclusive, amply satisfying the “re-read” agreed to by both FDA and the European Medicines Agency.
The NDA has been filed with a request for priority review, which would mean a 6-month review period if the request is granted. This is great news for radiologists who routinely struggle with limitations of MRI alone, trying to decipher from significantly less combined incoming visuals and instrumentation data whether or not such duct abnormalities are present. Needless to say, the quality of life and care improvement for patients is also immense.
President and CEO of REGN, Walter Herlihy, thanking the dedication and hard work of employees, clinical investigators and consultants, praised this milestone achievement for the Company as having the potential to become a standard tool for gastroenterology/radiology professionals to more competently diagnose and treat their patients.
Chief Medical Officer at RGEN, Dr. Michael Hall, projected a 60-day window for a response from FDA regarding acceptance of the application and priority review status, pledging to continue diligently working hand-in-hand with FDA as the process moves forward. Hall assured investors that every step was being taken to ensure complete success of the Company’s first NDA and pointed to previous fast track designation status granted to SecreFlo as a non-invasive alternative to dangerous diagnosis/treatment procedures like ERCP (endoscopic retrograde cholangiopancreatography; essentially, gastrointestinal endoscopy plus x rays).
The huge market, with over 300k MRIs in the US/Europe alone annually that could benefit from SecreFlo, and obvious potential is underwritten by a previously granted orphan drug designation, qualifying RGEN for seven years of marketing exclusivity if the Company is first to obtain approval for SecreFlo in combination with MRI. Additionally, RGEN is already planning a similar strategic move in Europe with the move to file a marketing authorization application next quarter.
For more information on the NDA, or on Repligen Corp., please visit the Company’s website at: www.Repligen.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
SecreFlo (RG1068, synthetic human secretin) is a powerful tool for vastly improving detection rates of abnormalities in the ducts of the pancreas during MRI examination for pancreatitis, which is characterized by such structural abnormalities and related serious abdominal pain. Increased sensitivity, image quality and the overall ability to have total visualization of the entire length of the pancreatic ducts, was validated for SecreFlo in the pivotal Phase 3 study, where MRI examination using the agent generated statistical improvements across all these key factors.
SecreFlo helps to stimulate fluid secretion in the pancreas, thus making visualization by MRI more effective. The multi-center, baseline controlled and single dose Phase 3 study of SecreFlo included 258 patients enrolled via 23 clinical sites throughout the U.S. and Canada. Evaluation for 10 pre-specified abnormalities against image quality, overall visualization and diagnostic capability data points was solid. Review by the team of three independent radiologists of the radiographic image data overturned the original analysis soundly, which was determined to be flawed and therefore inconclusive, amply satisfying the “re-read” agreed to by both FDA and the European Medicines Agency.
The NDA has been filed with a request for priority review, which would mean a 6-month review period if the request is granted. This is great news for radiologists who routinely struggle with limitations of MRI alone, trying to decipher from significantly less combined incoming visuals and instrumentation data whether or not such duct abnormalities are present. Needless to say, the quality of life and care improvement for patients is also immense.
President and CEO of REGN, Walter Herlihy, thanking the dedication and hard work of employees, clinical investigators and consultants, praised this milestone achievement for the Company as having the potential to become a standard tool for gastroenterology/radiology professionals to more competently diagnose and treat their patients.
Chief Medical Officer at RGEN, Dr. Michael Hall, projected a 60-day window for a response from FDA regarding acceptance of the application and priority review status, pledging to continue diligently working hand-in-hand with FDA as the process moves forward. Hall assured investors that every step was being taken to ensure complete success of the Company’s first NDA and pointed to previous fast track designation status granted to SecreFlo as a non-invasive alternative to dangerous diagnosis/treatment procedures like ERCP (endoscopic retrograde cholangiopancreatography; essentially, gastrointestinal endoscopy plus x rays).
The huge market, with over 300k MRIs in the US/Europe alone annually that could benefit from SecreFlo, and obvious potential is underwritten by a previously granted orphan drug designation, qualifying RGEN for seven years of marketing exclusivity if the Company is first to obtain approval for SecreFlo in combination with MRI. Additionally, RGEN is already planning a similar strategic move in Europe with the move to file a marketing authorization application next quarter.
For more information on the NDA, or on Repligen Corp., please visit the Company’s website at: www.Repligen.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Liberty Silver (LBSV) Closes $4.6M Financing, Announces Listing on Toronto Stock Exchange
Liberty Silver Corp., a company focused on exploring and developing mineral properties in North America, today announced it has closed a $4.6 million funding. The company also announced its acceptance for listing on the Toronto Stock Exchange, where it will trade under the symbol LSL effective Dec. 22, 2011.
The $4.6 million non-brokered private placement funding will support the exploration and development of its Trinity silver projects in Nevada, as well as for general working capital purposes.
The funding consisted of the sale of 2,627,500 units and 6,500,000 “Subscription Receipts,” which have been converted into 6,500,000 Units for an aggregate of 9,127,500 Units sold at U.S. $0.50 per unit. Each unit consists of one common share of Liberty Silver and one common share purchase warrant. Each whole warrant entitles the holder to acquire one common share at a price of U.S. $0.65 for a period of two years following the date of listing.
Liberty Silver’s 9,960-acre Trinity property is located in what the company believes to be a “mining friendly” district in Nevada. The property includes a former producing mine that represents approximately 1 percent of the geographic extent of the project. Based on the interpretation of the geologic data and past drilling data, the company suggests that the Trinity property may contain additional drilling targets which have not yet been identified.
The Trinity silver project reflects Liberty Silver’s plan to implement a mitigated risk development strategy. The first step in this process was to locate in a mining safe political jurisdiction. Additional efforts include: building a solid management team; determining previous proven minability of the property , such as permits, metallurgy, access and environmental issues; obtaining a National Instrument 43-101 mineral resource estimate technical report; historic data and recent geophysical surveys confirming eight exploration targets and two extensions from the original mine; and an ability to potentially mine quickly should uncertain market conditions warrant alternate means of financing the further development of the property.
“We are very pleased with the progress on the Trinity property,” Bill Tafuri, president and COO of Liberty Silver stated in the press release. “Our 43-101 Report indicates a property of merit that contains a defined silver resource, which could be expanded through further drilling. Our team has identified and confirmed multiple silver and gold targets not discussed in the 43-101 Report. With the funding in place, we expect to initiate additional geochemical and geophysical surveys in conjunction with an aggressive drilling campaign targeting both high priority exploration targets, and the extensions from the original pit. Given our geographical location, the quality of historical data, and our geological interpretations, we anticipate the planned programs could expand the current resources and help to define the potential for a profitable mine.”
For more information visit: www.libertysilvercorp.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The $4.6 million non-brokered private placement funding will support the exploration and development of its Trinity silver projects in Nevada, as well as for general working capital purposes.
The funding consisted of the sale of 2,627,500 units and 6,500,000 “Subscription Receipts,” which have been converted into 6,500,000 Units for an aggregate of 9,127,500 Units sold at U.S. $0.50 per unit. Each unit consists of one common share of Liberty Silver and one common share purchase warrant. Each whole warrant entitles the holder to acquire one common share at a price of U.S. $0.65 for a period of two years following the date of listing.
Liberty Silver’s 9,960-acre Trinity property is located in what the company believes to be a “mining friendly” district in Nevada. The property includes a former producing mine that represents approximately 1 percent of the geographic extent of the project. Based on the interpretation of the geologic data and past drilling data, the company suggests that the Trinity property may contain additional drilling targets which have not yet been identified.
The Trinity silver project reflects Liberty Silver’s plan to implement a mitigated risk development strategy. The first step in this process was to locate in a mining safe political jurisdiction. Additional efforts include: building a solid management team; determining previous proven minability of the property , such as permits, metallurgy, access and environmental issues; obtaining a National Instrument 43-101 mineral resource estimate technical report; historic data and recent geophysical surveys confirming eight exploration targets and two extensions from the original mine; and an ability to potentially mine quickly should uncertain market conditions warrant alternate means of financing the further development of the property.
“We are very pleased with the progress on the Trinity property,” Bill Tafuri, president and COO of Liberty Silver stated in the press release. “Our 43-101 Report indicates a property of merit that contains a defined silver resource, which could be expanded through further drilling. Our team has identified and confirmed multiple silver and gold targets not discussed in the 43-101 Report. With the funding in place, we expect to initiate additional geochemical and geophysical surveys in conjunction with an aggressive drilling campaign targeting both high priority exploration targets, and the extensions from the original pit. Given our geographical location, the quality of historical data, and our geological interpretations, we anticipate the planned programs could expand the current resources and help to define the potential for a profitable mine.”
For more information visit: www.libertysilvercorp.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tuesday, December 20, 2011
Biostar Pharmaceuticals (BSPM) Signs 1-Year Distribution Agreement in China
Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases afflicting the Chinese population.
The company announced today that its newly acquired subsidiary, Shaanxi Weinan, signed a 1-year distribution agreement with Shaanxi Huikang Pharmaceuticals Company effective January 1, 2012. Huikang Pharmaceuticals is a distributor of pharmaceutical products in 11 provinces in northwest and northern China and has a network of over 300 drugstores and hospitals.
Huikang Pharmaceuticals will distribute ten Biostar products. These products include six existing products which are currently being distributed through Biostar’s own network, covering 25 provinces, and four new products which are now being manufactured by Biostar. The four products include a remedy to fight the common cold, an anti-bacterial, anti-inflammatory drug, and drugs for the treatment of coronary heart disease and cerebrovascular disease.
All ten products will be ready for mass distribution through Huikang’s network starting in January 2012. Biostar anticipates this agreement will allow it to book annual sales of 30.4 million renminbi from the sale of these products. The amount may be higher if Huikang finds it needs more of the drugs due to high demand.
For additional information about Biostar Pharmaceuticals and its portfolio of products, please visit the company’s website at www.biostarpharmaceuticals.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The company announced today that its newly acquired subsidiary, Shaanxi Weinan, signed a 1-year distribution agreement with Shaanxi Huikang Pharmaceuticals Company effective January 1, 2012. Huikang Pharmaceuticals is a distributor of pharmaceutical products in 11 provinces in northwest and northern China and has a network of over 300 drugstores and hospitals.
Huikang Pharmaceuticals will distribute ten Biostar products. These products include six existing products which are currently being distributed through Biostar’s own network, covering 25 provinces, and four new products which are now being manufactured by Biostar. The four products include a remedy to fight the common cold, an anti-bacterial, anti-inflammatory drug, and drugs for the treatment of coronary heart disease and cerebrovascular disease.
All ten products will be ready for mass distribution through Huikang’s network starting in January 2012. Biostar anticipates this agreement will allow it to book annual sales of 30.4 million renminbi from the sale of these products. The amount may be higher if Huikang finds it needs more of the drugs due to high demand.
For additional information about Biostar Pharmaceuticals and its portfolio of products, please visit the company’s website at www.biostarpharmaceuticals.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR Offers Comprehensive Suite of Services to Execute Effective Investor Relations Strategy
Through a full suite of investor relations services, MissionIR is able to custom tailor the most effective communication strategy for its clients. By utilizing a comprehensive database, MissionIR strategically matches those clients with brokers, hedge funds, money managers, professional traders, and other individuals or institutions that are most likely to invest.
Recognizing that the most successful investor relations programs are in complete sync with broader strategic goals, MissionIR offers its clients a variety of services and solutions, including:
Corporate Counseling
Conferences
E-mail Marketing
Executive Videos/Interviews
Financing Support
Group Meetings
Handling of Investor Inquires
News Release Assistance
Presentations
Private Meetings
Road Shows
Social Networking
MissionIR provides an outsourced low-cost equivalent to an internal investor relations department while simultaneously offering a solid working knowledge of corporate finance and corporate strategy. Through a team of professionals, MissionIR provides a complete and comprehensive IR department requiring only a minimum amount of attention from executives, leaving them gratis to focus on their business.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Recognizing that the most successful investor relations programs are in complete sync with broader strategic goals, MissionIR offers its clients a variety of services and solutions, including:
Corporate Counseling
Conferences
E-mail Marketing
Executive Videos/Interviews
Financing Support
Group Meetings
Handling of Investor Inquires
News Release Assistance
Presentations
Private Meetings
Road Shows
Social Networking
MissionIR provides an outsourced low-cost equivalent to an internal investor relations department while simultaneously offering a solid working knowledge of corporate finance and corporate strategy. Through a team of professionals, MissionIR provides a complete and comprehensive IR department requiring only a minimum amount of attention from executives, leaving them gratis to focus on their business.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
FluoroPharma Medical, Inc. (FPMI) Raises a Collective Total of $7M in 2011
FluoroPharma Medical, Inc., a company specializing in the development of breakthrough diagnostic imaging products that utilize positron emission tomography (PET) technology to detect and assess pathology before clinical manifestation of diseases, announced this morning that they have secured an additional $1.010 million, bringing the total to more than $7 million over the course of 2011 from institutional and accredited investors.
“We are excited by the opportunities this additional working capital creates for FluoroPharma to significantly accelerate development of our pipeline,” stated Thijs Spoor, FluoroPharma’s President and CEO. “The funding will allow us to further advance our most promising portfolio of diagnostic imaging products, providing healthcare professionals with new products that expand and improve their diagnostic capabilities and contribute to earlier, more accurate diagnosis and treatment of disease– even before symptoms appear.”
Dr. David Elmaleh, Chairman of FluoroPharma’s Board of Directors added, “We are pleased that we have the resources to advance our clinical plans and achieve significant development milestones.”
Further details of the additional funds raised are available in the company’s most recent 8k.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“We are excited by the opportunities this additional working capital creates for FluoroPharma to significantly accelerate development of our pipeline,” stated Thijs Spoor, FluoroPharma’s President and CEO. “The funding will allow us to further advance our most promising portfolio of diagnostic imaging products, providing healthcare professionals with new products that expand and improve their diagnostic capabilities and contribute to earlier, more accurate diagnosis and treatment of disease– even before symptoms appear.”
Dr. David Elmaleh, Chairman of FluoroPharma’s Board of Directors added, “We are pleased that we have the resources to advance our clinical plans and achieve significant development milestones.”
Further details of the additional funds raised are available in the company’s most recent 8k.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Monday, December 19, 2011
Noble Financial Capital Markets BOCEMb 2012 Annual Equity Conference Held January 17-18, 2012
Noble Financial Capital Markets will be presenting its eighth annual BOCEMb equity conference at the Hard Rock Hotel & Casino in Hollywood (Ft. Lauderdale), Florida, January 17-18, 2012. The conference will feature approximately 140 public companies, as well as a few near-public companies, with an emphasis on healthcare, technology, software, defense and media / entertainment sectors.
Noble Financial’s senior equity research team evaluates nearly 1,000 potential presenters before deciding on the line-up. They target quality companies that may be undiscovered, underfollowed or perhaps orphaned; companies that may represent outstanding value for investors.
For additional information, contact Mark Pinvidic, Managing Partner, via email at mpinvidic@noblefcm.com or call (561) 994-5742.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Noble Financial’s senior equity research team evaluates nearly 1,000 potential presenters before deciding on the line-up. They target quality companies that may be undiscovered, underfollowed or perhaps orphaned; companies that may represent outstanding value for investors.
For additional information, contact Mark Pinvidic, Managing Partner, via email at mpinvidic@noblefcm.com or call (561) 994-5742.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Genetic Technologies Ltd. (GENE) Appoints Dr. Mel Bridges as New Chairman Replacing Sid Hack
Genetic Technologies Ltd., a leading-edge genetic testing and fertility services business from Australia that has an extensive range of international patents and allied research activities aimed at uncovering the impact of DNA on health, recently announced the appointment of Dr. Mel Bridges as their new Chairman and non-executive director of the Company. Dr. Mel Bridges has an extensive healthcare and diagnostic resume including the founding and managing of leading major diagnostics, therapeutics and medical device businesses like ASX listed Panbio Ltd. and ImpediMed Ltd. During his 30 year career, he has also served in prominent roles as director and chairman at other public healthcare companies, including Alcehmia Ltd., ImpediMed Ltd. Campbell Brothers, Benitec Ltd. and Peptech Ltd.
“Genetic Technologies has been one of the most compelling turnaround stories on the ASX and NASDAQ this year, and looks especially poised for growth as we head into 2012,” said Dr. Mel Bridges, new Chairman, Genetic Technologies, in a press release. “The Company’s progress to commercialization and recent US expansion is a credit to the existing Board and management. I am excited to utilize my experience in the sector to build on this trajectory.”
Dr. Bridges replaces Sid Hack who is retiring from the company where he has served as Director since November 2008 and Chairman since November 2009. Hack guided the company during restructuring and created a strategy for future growth that increased shareholder value.
“I am delighted that Mel has agreed to join the Board. His substantial and direct experience in the commercialization of diagnostics products globally will add tremendous value to the Company. In particular, his knowledge of the breast cancer diagnostics market in North America will help to accelerate the Company’s cancer diagnostics business in the USA,” said Sid Hack, retiring Chairman, Genetic Technologies, in the recent press release.
Over the past twenty years, Genetic Technologies has been granted patents in 24 countries for its uses of non-coding DNA in genetic analysis and gene mapping in all species. The company started offering paternity testing in 1997 and in 2004 became Australia’s largest privately owned forensic laboratory testing crime scent materials for the police. In 2004, the company became Australia’s first test for breast cancer and today is one of the largest providers in Australia for the private medical market. The corporate goal is to develop a portfolio of cancer management products and services on a global scale.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“Genetic Technologies has been one of the most compelling turnaround stories on the ASX and NASDAQ this year, and looks especially poised for growth as we head into 2012,” said Dr. Mel Bridges, new Chairman, Genetic Technologies, in a press release. “The Company’s progress to commercialization and recent US expansion is a credit to the existing Board and management. I am excited to utilize my experience in the sector to build on this trajectory.”
Dr. Bridges replaces Sid Hack who is retiring from the company where he has served as Director since November 2008 and Chairman since November 2009. Hack guided the company during restructuring and created a strategy for future growth that increased shareholder value.
“I am delighted that Mel has agreed to join the Board. His substantial and direct experience in the commercialization of diagnostics products globally will add tremendous value to the Company. In particular, his knowledge of the breast cancer diagnostics market in North America will help to accelerate the Company’s cancer diagnostics business in the USA,” said Sid Hack, retiring Chairman, Genetic Technologies, in the recent press release.
Over the past twenty years, Genetic Technologies has been granted patents in 24 countries for its uses of non-coding DNA in genetic analysis and gene mapping in all species. The company started offering paternity testing in 1997 and in 2004 became Australia’s largest privately owned forensic laboratory testing crime scent materials for the police. In 2004, the company became Australia’s first test for breast cancer and today is one of the largest providers in Australia for the private medical market. The corporate goal is to develop a portfolio of cancer management products and services on a global scale.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
BI-LO to Pay Winn-Dixie Stores, Inc. (WINN) Shareholders a Premium Price as Companies Announce Merger
Today, private company BI-LO, LLC, operator of some 207 supermarkets and 116 in-store pharmacies in the US SE market, and Winn-Dixie Stores, Inc. (WINN), with their fleet of some 480 supermarkets/380 in-store pharmacies, announced a merger, resulting in an extremely formidable organization.
Terms of the agreement stipulate that:
• BI-LO acquires all outstanding WINN shares via a transaction ($560M value) not subject to any financing conditions
• WINN shareholders receive $9.50 in cash per common share (75% premium over the Dec. 16 closing price)
Transaction closure is projected within 60-120 days (subject to customary closing conditions and WINN shareholder approval), and until the merger is complete, both companies will continue normal operations under their respective structures/banners. Post-merger BI-LO and Winn-Dixie anticipate no closures of currently operating locations.
The transaction will essentially transform Winn-Dixie into a privately-held and wholly-owned subsidiary of BI-LO, with the stock being removed from the NASDAQ exchange. A bold and powerful move by BI-LO and WINN that consolidates into a real southeastern supermarket and in-store pharmacy juggernaut, capable of and thoroughly expecting to continue operating under both readily recognized and serviceable banners.
Chairman of BI-LO, Randall Onstead, underscored the absence of overlap, with BI-LO holding territory in NC, SC, TN and GA, and WINN holding FL, AL, LA, MI, and GA (solid territorial GA integration). Similar heritage for companies, similar brand presence and market dynamics, as well as the strength of each brand regionally, underpinned by the vast community extending out from what will be a 630-store and 36k employee cultural footprint – these are the qualities that make the resulting entity such a force to be reckoned with in the US SE.
Chairman, CEO and President of WINN, Peter Lynch, echoed the enthusiasm of BI-LO resoundingly, confident that not only will this significant cash premium for shareholders be an ideal fit for them, but the combined company will be much stronger than before, making it an ideal fit for the Company’s own infrastructural future as well. Lynch pointed to the continued advancement of mutual interests and abundant cross-pollination of people and ideas which span both organizations, explaining that the long-term benefit to everyone involved, from customers and suppliers to team members and the communities served.
The resulting executive management team and HQ location will shake out between the existing Greenville, SC (BI-LO), and Jacksonville, FL (WINN) locations, with a presence likely being maintained at both. This incredible strategy was negotiated by a special committee of the WINN Board, assembled from eight independent directors and an outstanding team of independent financial and legal advisors:
WINN Financial Team
• Exclusively provided by Goldman, Sachs & Co.
WINN Legal Team
• Paul, Weiss, Rifkind, Wharton & Garrison LLP advising the special committee
• King & Spalding LLP and Greenberg Traurig, P.A. acting as legal advisors to the Company
BI-LO Financial Team
• William Blair, Citi, The Food Partners, Deutsche Bank Securities, Inc. and Alvarez & Marsal Transaction Advisory Group
BI-LO Legal Team
• Gibson, Dunn & Crutcher LLP and Hunton & Williams LLP
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Terms of the agreement stipulate that:
• BI-LO acquires all outstanding WINN shares via a transaction ($560M value) not subject to any financing conditions
• WINN shareholders receive $9.50 in cash per common share (75% premium over the Dec. 16 closing price)
Transaction closure is projected within 60-120 days (subject to customary closing conditions and WINN shareholder approval), and until the merger is complete, both companies will continue normal operations under their respective structures/banners. Post-merger BI-LO and Winn-Dixie anticipate no closures of currently operating locations.
The transaction will essentially transform Winn-Dixie into a privately-held and wholly-owned subsidiary of BI-LO, with the stock being removed from the NASDAQ exchange. A bold and powerful move by BI-LO and WINN that consolidates into a real southeastern supermarket and in-store pharmacy juggernaut, capable of and thoroughly expecting to continue operating under both readily recognized and serviceable banners.
Chairman of BI-LO, Randall Onstead, underscored the absence of overlap, with BI-LO holding territory in NC, SC, TN and GA, and WINN holding FL, AL, LA, MI, and GA (solid territorial GA integration). Similar heritage for companies, similar brand presence and market dynamics, as well as the strength of each brand regionally, underpinned by the vast community extending out from what will be a 630-store and 36k employee cultural footprint – these are the qualities that make the resulting entity such a force to be reckoned with in the US SE.
Chairman, CEO and President of WINN, Peter Lynch, echoed the enthusiasm of BI-LO resoundingly, confident that not only will this significant cash premium for shareholders be an ideal fit for them, but the combined company will be much stronger than before, making it an ideal fit for the Company’s own infrastructural future as well. Lynch pointed to the continued advancement of mutual interests and abundant cross-pollination of people and ideas which span both organizations, explaining that the long-term benefit to everyone involved, from customers and suppliers to team members and the communities served.
The resulting executive management team and HQ location will shake out between the existing Greenville, SC (BI-LO), and Jacksonville, FL (WINN) locations, with a presence likely being maintained at both. This incredible strategy was negotiated by a special committee of the WINN Board, assembled from eight independent directors and an outstanding team of independent financial and legal advisors:
WINN Financial Team
• Exclusively provided by Goldman, Sachs & Co.
WINN Legal Team
• Paul, Weiss, Rifkind, Wharton & Garrison LLP advising the special committee
• King & Spalding LLP and Greenberg Traurig, P.A. acting as legal advisors to the Company
BI-LO Financial Team
• William Blair, Citi, The Food Partners, Deutsche Bank Securities, Inc. and Alvarez & Marsal Transaction Advisory Group
BI-LO Legal Team
• Gibson, Dunn & Crutcher LLP and Hunton & Williams LLP
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Vermillion, Inc. (VRML) Purchases Correlogic Systems’ Assets for $435,000
Leading molecular diagnostics company, Vermillion, Inc., announced today that it has completed purchasing almost all of the assets associated with Correlogic Systems, Inc., the ovarian cancer diagnostics business.
Before filing for bankruptcy protection under Chapter 11 in 2010, Correlogic pioneered the use of pattern recognition technologies in the development of proteomic, metabolomic and genomic-based clinical diagnostic tests. The company’s technology possessed a wide range of applications for creating disease classification models, biomarker discovery and new drug discovery processes. These initiatives led to cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications as published in 17 peer-reviewed journals.
Vermillion paid approximately $435,000 in cash for Correlogic’s assets, which included more than 1,000 diagnostic samples from ovarian tumor studies, three pending U.S. patents, proprietary software and other intellectual property. Vermillion will use these assets to advance its ovarian cancer franchise, including developing its next-generation ovarian cancer test, OVA2™. The company intends to use OVA2 to expand its ovarian cancer market opportunities by addressing unmet medical needs and additional indications for testing. Ultimately, by gaining Correlogic’s patient samples, Vermillion will enhance its strategic position as an industry leader.
“While Vermillion notes the loss of a substantial competitor, the acquisition of these assets will enhance our development efforts, and offers significant savings in terms of time and cost,” remarked Vermillion’s CEO, Gail Page. “Further, the acquisition adds to our growing IP portfolio.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Before filing for bankruptcy protection under Chapter 11 in 2010, Correlogic pioneered the use of pattern recognition technologies in the development of proteomic, metabolomic and genomic-based clinical diagnostic tests. The company’s technology possessed a wide range of applications for creating disease classification models, biomarker discovery and new drug discovery processes. These initiatives led to cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications as published in 17 peer-reviewed journals.
Vermillion paid approximately $435,000 in cash for Correlogic’s assets, which included more than 1,000 diagnostic samples from ovarian tumor studies, three pending U.S. patents, proprietary software and other intellectual property. Vermillion will use these assets to advance its ovarian cancer franchise, including developing its next-generation ovarian cancer test, OVA2™. The company intends to use OVA2 to expand its ovarian cancer market opportunities by addressing unmet medical needs and additional indications for testing. Ultimately, by gaining Correlogic’s patient samples, Vermillion will enhance its strategic position as an industry leader.
“While Vermillion notes the loss of a substantial competitor, the acquisition of these assets will enhance our development efforts, and offers significant savings in terms of time and cost,” remarked Vermillion’s CEO, Gail Page. “Further, the acquisition adds to our growing IP portfolio.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Friday, December 16, 2011
Noble Financial Capital Markets is a Full Service Investment Banking Boutique
Noble Financial Capital Markets, with offices around the country, defines itself as a full-service investment banking boutique, focused on private, micro-cap and small-cap emerging growth companies, with a special emphasis on Healthcare and Technology sectors. The company is known for identifying attractive growth companies and providing high quality capital markets coverage, using 10 senior research analysts covering 120 companies. In addition, Noble is a market maker in over 200 securities, with 16 senior sales and sales traders in 9 locations across the U.S. for focused institutional sales and trading.
Noble Financial’s services cover 5 primary areas:
• Investment Banking - IPOs, PIPEs & Registered Directs, Debt Offerings, Secondary Offerings, Private Equity Placements, and Recapitalizations
• Equity Research – Institutionally Driven, Fundamental Research, with access to company management and a sector focus on high-quality, under-valued, emerging growth companies with limited sponsorship
• Sales & Trading – Institutional Equity Sales, Equity Trading, Market Maker, Offices in New York, Boston, Los Angeles, St. Louis, San Francisco, and Boca Raton Florida
• Advisory – Mergers & Acquisitions, Fairness Opinions, General Advisory Services
• Merchant Banking – Principal Investments, Value Creation, Strategic Development
Healthcare represents Noble’s single largest industry focus, with equity research analysts covering the following main verticals:
• Biotechnology & Specialty Pharmaceuticals (antivirals, biosimilars, biobetters & orphan biologics, infectious disease, female health, neurology, pediatric health, stem cells, vaccines)
• Medical Technology/Devices (aesthetics, biologics, cardiology, orthopedics/spine)
• Healthcare Services (ambulatory surgery centers, chronic disease/wellness, disease management, pharmacy/PBM, care management solutions)
Current healthcare research coverage includes the following companies:
- Achillion Pharmaceuticals (ACHN)
- Acorda Therapeutics, Inc. (ACOR)
- Adcare Health Systems Inc.(ADK )
- Aeolus Pharmaceuticals (AOLS)
- Amarin Corporation (AMRN)
- American CareSource (ANSI)
- Anadys Pharmaceuticals (ANDS)
- Ardea Biosciences (RDEA)
- Auxilium Pharmaceuticals, Inc. (AUXL)
- BioMimetic (BMTI)
- BioScrip (BIOS)
- BioSpecifics Technologies Co. (BSTC)
- BioCryst Pharmaceuticals Inc. (BCRX)
- Catalyst Health Solutions (CHSI)
- Catalyst Pharmaceutical (CPRX)
- Cephalon, Inc. (CEPH)
- Cynosure (CYNO)
- Cytori Therapeutics (CYTX)
- DexCom (DXCM)
- Echo Therapeutics (ECTE)
- Edwards Lifesciences (EW)
- Exactech (EXAC)
- GenVec (GNVC)
- Hanger Orthopedic (HGR)
- Healthstream (HSTM)
- Healthways (HWAY)
- iBio, Inc. (IBIO)
- Idera Pharmaceuticals (IDRA)
- Inhibitex (INHX)
- Inovio Pharmaceuticals (INO)
- Nabi Biopharmaceuticals (NABI)
- Neuralstem, Inc. (CUR)
- Novamed (NOVA)
- Pernix Therapeutics (PTX )
- Pharmassett (VRUS)
- PharmAthene (PIP)
- PharMerica (PMC)
- PolyMedix (PYMX)
- Protalix BioTherapeutics (PLX)
- Providence Service Corp (PRSC)
- QRxPharma (QRX.AX)
- Res-Care (RCSR)
- Res-Care (RCSR)
- SIGA Technologies (SIGA)
- US Physical Therapy (USPH)
- Vical (VICL)
- Wright Medical (WMGI)
- XenoPort, Inc. (XNPT)
Other sectors covered include Business Services, Cleantech Energy, Defense Technology, Media & Entertainment.
For more information, see the company website at www.NobleFCM.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Noble Financial’s services cover 5 primary areas:
• Investment Banking - IPOs, PIPEs & Registered Directs, Debt Offerings, Secondary Offerings, Private Equity Placements, and Recapitalizations
• Equity Research – Institutionally Driven, Fundamental Research, with access to company management and a sector focus on high-quality, under-valued, emerging growth companies with limited sponsorship
• Sales & Trading – Institutional Equity Sales, Equity Trading, Market Maker, Offices in New York, Boston, Los Angeles, St. Louis, San Francisco, and Boca Raton Florida
• Advisory – Mergers & Acquisitions, Fairness Opinions, General Advisory Services
• Merchant Banking – Principal Investments, Value Creation, Strategic Development
Healthcare represents Noble’s single largest industry focus, with equity research analysts covering the following main verticals:
• Biotechnology & Specialty Pharmaceuticals (antivirals, biosimilars, biobetters & orphan biologics, infectious disease, female health, neurology, pediatric health, stem cells, vaccines)
• Medical Technology/Devices (aesthetics, biologics, cardiology, orthopedics/spine)
• Healthcare Services (ambulatory surgery centers, chronic disease/wellness, disease management, pharmacy/PBM, care management solutions)
Current healthcare research coverage includes the following companies:
- Achillion Pharmaceuticals (ACHN)
- Acorda Therapeutics, Inc. (ACOR)
- Adcare Health Systems Inc.(ADK )
- Aeolus Pharmaceuticals (AOLS)
- Amarin Corporation (AMRN)
- American CareSource (ANSI)
- Anadys Pharmaceuticals (ANDS)
- Ardea Biosciences (RDEA)
- Auxilium Pharmaceuticals, Inc. (AUXL)
- BioMimetic (BMTI)
- BioScrip (BIOS)
- BioSpecifics Technologies Co. (BSTC)
- BioCryst Pharmaceuticals Inc. (BCRX)
- Catalyst Health Solutions (CHSI)
- Catalyst Pharmaceutical (CPRX)
- Cephalon, Inc. (CEPH)
- Cynosure (CYNO)
- Cytori Therapeutics (CYTX)
- DexCom (DXCM)
- Echo Therapeutics (ECTE)
- Edwards Lifesciences (EW)
- Exactech (EXAC)
- GenVec (GNVC)
- Hanger Orthopedic (HGR)
- Healthstream (HSTM)
- Healthways (HWAY)
- iBio, Inc. (IBIO)
- Idera Pharmaceuticals (IDRA)
- Inhibitex (INHX)
- Inovio Pharmaceuticals (INO)
- Nabi Biopharmaceuticals (NABI)
- Neuralstem, Inc. (CUR)
- Novamed (NOVA)
- Pernix Therapeutics (PTX )
- Pharmassett (VRUS)
- PharmAthene (PIP)
- PharMerica (PMC)
- PolyMedix (PYMX)
- Protalix BioTherapeutics (PLX)
- Providence Service Corp (PRSC)
- QRxPharma (QRX.AX)
- Res-Care (RCSR)
- Res-Care (RCSR)
- SIGA Technologies (SIGA)
- US Physical Therapy (USPH)
- Vical (VICL)
- Wright Medical (WMGI)
- XenoPort, Inc. (XNPT)
Other sectors covered include Business Services, Cleantech Energy, Defense Technology, Media & Entertainment.
For more information, see the company website at www.NobleFCM.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Subscribe to:
Posts (Atom)